Drugname	NCIDS:Phase:Status:Literature	Targets
thiotepa	NCT00002515:Phase 2:Completed:No publish	html not right
topotecan hydrochloride	NCT00002515:Phase 2:Completed:No publish	html not right
mesna	NCT00002854:Phase 1:Completed:No publish	html not right
ifosfamide	NCT00002854:Phase 1:Completed:No publish;;NCT00003597:Phase 1:Completed:Angiolillo AL, Davenport V, Bonilla MA, van de Ven C, Ayello J, Militano O, Miller LL, Krailo M, Reaman G, Cairo MS; Children's Oncology Group. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005 Apr 1;11(7):2644-50.	Html not right
paclitaxel	NCT00002854:Phase 1:Completed:No publish;;NCT01953926:Phase 2:Recruiting:No publish;;NCT00508326:Phase 1:Completed:No publish	html not right
cisplatin-e therapeutic implant	NCT00003044:Phase 2:Unknown status:No publish	html not right
pegylated liposomal doxorubicin hydrochloride	NCT00003296:Phase 2:Unknown status:No publish	html not right
tamoxifen citrate	NCT00003424:Phase 3:Completed:No publish	html not right
aminocamptothecin colloidal dispersion	NCT00003548:Phase 1:Completed:No publish	html not right
dolastatin 10	NCT00003557:Phase 2:Completed:No publish	html not right
doxorubicin	NCT00003907:Phase 2:Completed:No publish;;NCT00083226:Phase 2:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00988195:Phase 1:Completed:No publish;;NCT01858207:Phase 2:Unknown status:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT01272557:Phase 2:Unknown status:No publish;;NCT03145558:Phase 2:Recruiting:No publish;;NCT01840592:Phase 2:Active, not recruiting:No publish;;NCT01655693:Phase 3:Active, not recruiting:No publish;;NCT00990860:Phase 2:Unknown status:No publish;;NCT00471965:Phase 3:Completed:No publish	html not right
mitomycin	NCT00003907:Phase 2:Completed:No publish;;NCT01004978:Phase 3:Active, not recruiting:No publish	html not right
carboplatin	NCT00003912:Phase 3:Completed:Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.;;NCT00875615:Phase 2:Completed:No publish;;NCT00077389:Phase 2:Unknown status:No publish;;NCT00003994:Phase 3:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00486356:Phase 1:Completed:No publish;;NCT00021047:Phase 1|Phase 2:Completed:No publish;;NCT00007813:Phase 1:Unknown status:Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.;;NCT00002515:Phase 2:Completed:No publish;;NCT00303940:Phase 1:Completed:Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.;;NCT00002854:Phase 1:Completed:No publish;;NCT02755311:Phase 3:Unknown status:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT00003597:Phase 1:Completed:Angiolillo AL, Davenport V, Bonilla MA, van de Ven C, Ayello J, Militano O, Miller LL, Krailo M, Reaman G, Cairo MS; Children's Oncology Group. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005 Apr 1;11(7):2644-50.	Html not right
cisplatin	NCT00003912:Phase 3:Completed:Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.;;NCT00875615:Phase 2:Completed:No publish;;NCT00276705:Phase 2:Unknown status:No publish;;NCT00652132:Phase 3:Completed:No publish;;NCT00003907:Phase 2:Completed:No publish;;NCT00077389:Phase 2:Unknown status:No publish;;NCT01042041:Phase 1:Completed:No publish;;NCT00003994:Phase 3:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00304135:Phase 2|Phase 3:Completed:Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F��d��ration Francophone de Canc��rologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.;;NCT01004978:Phase 3:Active, not recruiting:No publish;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT00010023:Phase 1:Completed:Chen TT, Ryan T, Potmesil M, et al.: Cisplatin/capecitabine: tolerance and activity in patients with upper gastrointestinal cancers. [Abstract] American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 22-24 January 2004, San Francisco, CA. A-53, 2004.;;NCT00002854:Phase 1:Completed:No publish;;NCT00843934:Phase 2|Phase 3:Unknown status:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT03268499:Phase 2:Recruiting:No publish;;NCT00524498:Phase 2:Completed:No publish;;NCT00507962:Phase 1:Completed:No publish;;NCT00023868:Phase 3:Completed:No publish	Html not right
doxorubicin hydrochloride	NCT00003912:Phase 3:Completed:Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.;;NCT01011010:Phase 1:Completed:No publish;;NCT00004248:Phase 2:Completed:No publish;;NCT00012324:Phase 3:Completed:Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 Jul 20;25(21):3069-75.;;NCT00471484:Phase 2:Unknown status:Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):159-65.;;NCT00079027:Phase 3:Unknown status:No publish;;NCT00276705:Phase 2:Unknown status:No publish;;NCT00047229:Phase 2:Completed:Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs. 2008 Apr;26(2):193-4. Epub 2007 Dec 4.;;NCT00006016:Phase 2:Completed:No publish;;NCT00077389:Phase 2:Unknown status:No publish;;NCT01042041:Phase 1:Completed:No publish;;NCT01004978:Phase 3:Active, not recruiting:No publish;;NCT01015833:Phase 3:Active, not recruiting:No publish;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT00720174:Phase 1:Completed:No publish;;NCT00023868:Phase 3:Completed:No publish	html not right
porfimer sodium	NCT00003923:Phase 2:Completed:No publish	html not right
amifostine trihydrate	NCT00003994:Phase 3:Completed:No publish	html not right
vincristine sulfate	NCT00003994:Phase 3:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00980460:Phase 3:Active, not recruiting:No publish	html not right
exatecan mesylate	NCT00004108:Phase 2:Completed:No publish;;NCT00005938:Phase 2:Completed:No publish	html not right
fluorouracil (5-fu)	NCT00004142:Phase 2:Completed:No publish	html not right
tipifarnib	NCT00005842:Phase 1:Completed:Schwartz G, Rowinsky EK, Rha SY, et al.: A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-322, 2001.	html not right
thalidomide	NCT00006006:Phase 2:Completed:Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist. 2005 Oct;10(9):718-27.;;NCT00058487:Phase 2:Completed:Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul;10(6):392-8.;;NCT00276705:Phase 2:Unknown status:No publish;;NCT00006198:Phase 2:Unknown status:No publish;;NCT00006016:Phase 2:Completed:No publish;;NCT00728078:Phase 2|Phase 3:Unknown status:Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8.;;NCT00049296:Phase 1:Completed:Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs. 2008 Aug;26(4):355-62. doi: 10.1007/s10637-008-9137-0. Epub 2008 May 10.;;NCT00155272:Phase 1|Phase 2:Unknown status:No publish;;NCT00921531:Phase 3:Unknown status:No publish;;NCT00519688:Phase 2:Completed:No publish	Html not right
docetaxel	NCT00006010:Phase 2:Completed:Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct;35(5):418-23.;;NCT00049296:Phase 1:Completed:Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs. 2008 Aug;26(4):355-62. doi: 10.1007/s10637-008-9137-0. Epub 2008 May 10.;;NCT00002901:Phase 1:Completed:No publish	html not right
tetrathiomolybdate	NCT00006332:Phase 2:Completed:No publish	html not right
nolatrexed dihydrochloride	NCT00012324:Phase 3:Completed:Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 Jul 20;25(21):3069-75.	html not right
ondansetron	NCT00016380:Phase 3:Completed:National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006 Jul 20;24(21):3458-64.	html not right
detoxpc	NCT00019331:Phase 2:Completed:No publish	html not right
hydroxyurea	NCT00019474:Phase 2:Unknown status:No publish	html not right
doxorubicin hcl liposome	NCT00019630:Phase 1:Completed:No publish	html not right
o6-benzylguanine	NCT00020150:Phase 1:Completed:Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2009 Dec;65(1):137-42. doi: 10.1007/s00280-009-1015-8. Epub 2009 May 9.	Html not right
folfiri regimen	NCT00020501:Phase 3:Completed:No publish;;NCT00023868:Phase 3:Completed:No publish	html not right
entinostat	NCT00020579:Phase 1:Completed:Ryan QC, Headlee D, Sparreboom A, et al.: A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-802, 2003.	html not right
melphalan	NCT00030082:Phase 1:Completed:No publish;;NCT00001587:Phase 1:Completed:No publish;;NCT00019786:Phase 2:Completed:Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003 Dec 15;21(24):4560-7.;;NCT00001576:Phase 1:Completed:No publish;;NCT00096083:Phase 2:Completed:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00089401:Phase 2:Completed:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT00019760:Phase 2:Completed:No publish	Html not right
isolated perfusion	NCT00030082:Phase 1:Completed:No publish;;NCT00019786:Phase 2:Completed:Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003 Dec 15;21(24):4560-7.;;NCT00096083:Phase 2:Completed:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00089401:Phase 2:Completed:No publish;;NCT00002692:Phase 3:Unknown status:Current version of study NCT00002692 on ClinicalTrials.gov;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.	html not right
ixabepilone	NCT00030108:Phase 1:Completed:Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol. 2009 Feb 1;27(4):550-6. doi: 10.1200/JCO.2008.17.6644. Epub 2008 Dec 15.	html not right
7-hydroxystaurosporine	NCT00031681:Phase 1:Completed:No publish	html not right
abt-751	NCT00036959:Phase 1:Completed:Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, Medina D, Xiong H, Krivoshik A, Widemann B, Adamson PC, Balis FM. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. doi: 10.1007/s00280-009-1218-z. Epub 2010 Jan 1.	Html not right
megestrol acetate	NCT00041275:Phase 3:Completed:Chow PK, Machin D, Chen Y, Zhang X, Win KM, Hoang HH, Nguyen BD, Jin MY, Lobo R, Findlay M, Lim CH, Tan SB, Gandhi M, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer. 2011 Sep 27;105(7):945-52. doi: 10.1038/bjc.2011.333. Epub 2011 Aug 23.	html not right
intravenous t900607-sodium	NCT00043433:Phase 2:Unknown status:No publish	html not right
bms-247550	NCT00049400:Phase 1:Completed:Current version of study NCT00049400 on ClinicalTrials.gov	html not right
t900607	NCT00054262:Phase 2:Completed:No publish	html not right
mtc-dox for injection	NCT00054951:Phase 1|Phase 2:Unknown status:No publish;;NCT00041808:Phase 1|Phase 2:Completed:No publish	html not right
aroplatin (liposomal nddp, l-nddp)	NCT00057395:Phase 1|Phase 2:Unknown status:No publish	html not right
celecoxib	NCT00057980:Phase 1|Phase 2:Completed:No publish;;NCT00081848:Phase 1:Completed:No publish;;NCT02961998:Phase 4:Completed:No publish;;NCT03403634:Early Phase 1:Recruiting:No publish	Html not right
epirubicin hydrochloride	NCT00058487:Phase 2:Completed:Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul;10(6):392-8.;;NCT00057980:Phase 1|Phase 2:Completed:No publish;;NCT00486356:Phase 1:Completed:No publish;;NCT00021047:Phase 1|Phase 2:Completed:No publish	html not right
pemetrexed disodium	NCT00059865:Phase 1|Phase 2:Completed:Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer. 2007;38(2-4):87-94. doi: 10.1007/s12029-008-9037-8. Epub 2008 Nov 21.	html not right
boronophenylalanine-fructose complex	NCT00062348:Phase 1:Completed:Wittig A, Sheu-Grabellus SY, Collette L, Moss R, Brualla L, Sauerwein W. BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). Appl Radiat Isot. 2011 Dec;69(12):1807-12. doi: 10.1016/j.apradiso.2011.02.018. Epub 2011 Feb 16.	html not right
sodium borocaptate	NCT00062348:Phase 1:Completed:Wittig A, Sheu-Grabellus SY, Collette L, Moss R, Brualla L, Sauerwein W. BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). Appl Radiat Isot. 2011 Dec;69(12):1807-12. doi: 10.1016/j.apradiso.2011.02.018. Epub 2011 Feb 16.	html not right
gefitinib	NCT00071994:Phase 2:Completed:No publish	Html not right
mb07133 300mg/m2/day	NCT00073736:Phase 1|Phase 2:Completed:No publish	html not right
mb07133 600 mg/m2/day	NCT00073736:Phase 1|Phase 2:Completed:No publish	html not right
mb07133 1200 mg/m2/day	NCT00073736:Phase 1|Phase 2:Completed:No publish	html not right
mb07133 1800 mg/m2/day	NCT00073736:Phase 1|Phase 2:Completed:No publish	html not right
mb07133 2400 mg/m2/day	NCT00073736:Phase 1|Phase 2:Completed:No publish	html not right
capecitabine plus gemcitabine	NCT00073905:Phase 2:Completed:Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008 Aug 1;26(22):3702-8. doi: 10.1200/JCO.2008.16.5704.	html not right
forodesine hydrochloride	NCT00073944:Phase 1:Completed:No publish	html not right
phy906	NCT00076609:Phase 1|Phase 2:Completed:No publish	html not right
tac-101	NCT00077142:Phase 1|Phase 2:Completed:Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008 Dec;134(12):1325-35. doi: 10.1007/s00432-008-0406-2. Epub 2008 May 27.	html not right
idn-6556	NCT00080236:Phase 2:Completed:No publish	html not right
rv-cea(6d)/tricom-rf-cea(6d)/tricom	NCT00081848:Phase 1:Completed:No publish	html not right
rf-cea(6d)/tricom	NCT00081848:Phase 1:Completed:No publish	html not right
recombinant fowlpox-gm-csf	NCT00081848:Phase 1:Completed:No publish	html not right
thymalfasin (thymosin alpha-1)	NCT00082082:Phase 2:Completed:No publish	html not right
bortezomib	NCT00083226:Phase 2:Completed:No publish;;NCT00077441:Phase 2:Completed:No publish;;NCT00091117:Phase 1:Completed:No publish	Html not right
alvocidib	NCT00087282:Phase 2:Completed:No publish;;NCT00012181:Phase 1:Completed:No publish	html not right
irinotecan hydrochloride	NCT00087282:Phase 2:Completed:No publish;;NCT00287976:Phase 2:Unknown status:No publish;;NCT00537121:Phase 1:Completed:No publish;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT00654160:Phase 1:Completed:No publish;;NCT00003427:Phase 1:Completed:Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.;;NCT00031681:Phase 1:Completed:No publish;;NCT01643499:Phase 1:Active, not recruiting:No publish;;NCT00101270:Phase 1:Completed:No publish;;NCT00003867:Phase 1:Unknown status:Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00513266:Phase 2:Unknown status:No publish;;NCT00023868:Phase 3:Completed:No publish;;NCT00063960:Phase 2:Completed:No publish;;NCT00557102:Phase 2:Completed:No publish;;NCT00003368:Phase 1:Completed:Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec;14(12):1783-90.;;NCT00003753:Phase 2:Completed:No publish;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00030563:Phase 2:Completed:No publish	html not right
lyso-thermosensitive liposomal doxorubicin	NCT00093444:Phase 1:Completed:No publish	html not right
ns-9 [poly i: poly c]	NCT00094003:Phase 1:Completed:No publish	html not right
ispinesib	NCT00095992:Phase 2:Completed:Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs. 2008 Jun;26(3):265-72. doi: 10.1007/s10637-007-9103-2. Epub 2008 Jan 15.	html not right
lapatinib ditosylate	NCT00101036:Phase 2:Completed:No publish;;NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.	html not right
sorafenib (nexavar, bay43-9006)	NCT00105443:Phase 3:Completed:Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.;;NCT00044512:Phase 2:Completed:Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.;;NCT00494299:Phase 3:Completed:Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.;;NCT00901901:Phase 3:Completed:No publish;;NCT00855218:Phase 2:Completed:No publish;;NCT00492752:Phase 3:Completed:Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.	html not right
sorafenib (nexavar, bay43-9006) plus doxorubicin	NCT00108953:Phase 2:Completed:Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.	html not right
doxorubicin/placebo	NCT00108953:Phase 2:Completed:Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.	html not right
131 i-lipiodol	NCT00116454:Phase 3:Completed:No publish	html not right
talaporfin sodium	NCT00122876:Phase 1|Phase 2:Completed:No publish	html not right
arsenic trioxide	NCT00128596:Phase 2:Completed:No publish;;NCT00024258:Phase 2:Completed:No publish;;NCT02956772:Phase 2:Not yet recruiting:No publish	html not right
irinotecan + 5 fu + folinic acid	NCT00143403:Phase 3:Completed:No publish	html not right
folinic acid + 5 fu	NCT00143403:Phase 3:Completed:No publish	html not right
nv1020	NCT00149396:Phase 1|Phase 2:Completed:No publish	html not right
ifn-α2b	NCT00149565:Phase 3:Completed:No publish	html not right
cetuximab and folfiri	NCT00153998:Phase 2:Completed:No publish	html not right
cetuximab and folfox	NCT00153998:Phase 2:Completed:No publish	html not right
perioperative chemotherapy	NCT00168155:Phase 2:Completed:No publish	html not right
oral nutritional supplement rich in eicosapentanoic acid	NCT00168987:Phase 4:Completed:No publish	html not right
mitomycin-c, cisplatin	NCT00183885:Phase 2:Active, not recruiting:No publish	html not right
recombinant human thrombopoietin	NCT00187109:Phase 1|Phase 2:Completed:No publish	html not right
pemetrexed	NCT00191412:Phase 2:Completed:No publish	html not right
bevacizumab hai plus systemic chemotherapy	NCT00200200:Phase 2:Active, not recruiting:No publish	html not right
hai plus systemic chemotherapy	NCT00200200:Phase 2:Active, not recruiting:No publish	html not right
folfiri	NCT00208260:Phase 2|Phase 3:Completed:No publish	html not right
folfox-4	NCT00208260:Phase 2|Phase 3:Completed:No publish	html not right
folfiri-hd	NCT00208260:Phase 2|Phase 3:Completed:No publish	html not right
folfox-7	NCT00208260:Phase 2|Phase 3:Completed:No publish	html not right
folfirinox	NCT00208260:Phase 2|Phase 3:Completed:No publish	html not right
interferon alpha-2b	NCT00234182:Phase 1|Phase 2:Completed:No publish;;NCT00273247:Phase 3:Completed:No publish	html not right
cediranib maleate	NCT00238394:Phase 2:Completed:No publish	html not right
octreotide	NCT00241020:Phase 3:Completed:No publish	html not right
erlotinib	NCT00242502:Phase 2:Completed:No publish;;NCT01180959:Phase 2:Active, not recruiting:No publish;;NCT00287222:Phase 2:Completed:No publish	Html not right
sunitinib (su011248)	NCT00247676:Phase 2:Completed:No publish	html not right
pi-88	NCT00247728:Phase 2:Completed:No publish	html not right
thalidomide, alpha interferon	NCT00250796:Phase 2:Completed:No publish	html not right
thalidomide, interferon, octreotide	NCT00250796:Phase 2:Completed:No publish	html not right
gemcitabine and oxaliplatin	NCT00250822:Phase 2:Completed:No publish	html not right
octreotide acetate	NCT00257426:Phase 2:Completed:No publish	html not right
adh300004	NCT00264446:Phase 1:Completed:No publish	html not right
patupilone	NCT00273312:Phase 2:Completed:Zhou Q, Wong CH, Lau CP, Hui CW, Lui VW, Chan SL, Yeo W. Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:103830. doi: 10.1155/2013/103830. Epub 2013 Feb 20.	html not right
cyclophosphamide	NCT00276705:Phase 2:Unknown status:No publish;;NCT03159585:Phase 1:Recruiting:No publish;;NCT02869217:Phase 1:Recruiting:No publish;;NCT01967823:Phase 2:Recruiting:No publish;;NCT00007813:Phase 1:Unknown status:Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.;;NCT00002854:Phase 1:Completed:No publish;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT03084380:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT01174121:Phase 2:Recruiting:No publish;;NCT00656123:Phase 1:Unknown status:No publish	html not right
e7337	NCT00280410:Phase 2|Phase 3:Completed:No publish	html not right
iressa	NCT00282100:Phase 2:Unknown status:No publish	html not right
talabostat mesylate	NCT00303940:Phase 1:Completed:Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.	html not right
temozolomide	NCT00303940:Phase 1:Completed:Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.;;NCT00020150:Phase 1:Completed:Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2009 Dec;65(1):137-42. doi: 10.1007/s00280-009-1015-8. Epub 2009 May 9.;;NCT00526617:Phase 1:Completed:Nuthalapati S, Munasinghe W, Giranda V, Xiong H. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clin Pharmacokinet. 2018 Jan;57(1):51-58. doi: 10.1007/s40262-017-0547-z.	html not right
belinostat	NCT00321594:Phase 1|Phase 2:Completed:No publish	Html not right
crs-100	NCT00327652:Phase 1:Completed:No publish	html not right
embolization therapy	NCT00335829:Phase 2:Completed:No publish;;NCT00028626:Phase 2:Completed:No publish	html not right
chemotherapy	NCT00335829:Phase 2:Completed:No publish;;NCT02862587:Phase 1|Phase 2:Recruiting:No publish;;NCT02363049:Phase 3:Recruiting:No publish;;NCT02738606:Phase 2:Recruiting:No publish	html not right
brivanib (active)	NCT00355238:Phase 2:Completed:No publish	html not right
cni, mmf, steroids, aza etc. (mtor inhibitor free)	NCT00355862:Phase 3:Completed:No publish	html not right
su011248	NCT00361309:Phase 2:Completed:No publish	html not right
nicotine lozenge	NCT00365508:Phase 4:Completed:No publish	html not right
nicotine patch	NCT00365508:Phase 4:Completed:No publish	html not right
pazopanib	NCT00370513:Phase 1:Completed:No publish;;NCT00674024:Phase 1:Completed:No publish	Html not right
irofulven + oxaliplatin	NCT00374660:Phase 1|Phase 2:Unknown status:No publish	html not right
rapamycin (sirolimus)	NCT00375245:Phase 1:Completed:No publish	html not right
interferon-alfa-2b and ribavirin	NCT00375661:Phase 4:Completed:No publish	html not right
thalidomide(thado), tegafur/uracil(ufur)	NCT00384800:Phase 2:Unknown status:No publish	html not right
somatostatin (octreotide)	NCT00386984:Phase 3:Completed:Allgaier HP, Becker G, Blum HE. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide]. Dtsch Med Wochenschr. 2000 Mar 17;125(11):320. German.	html not right
rad001 (everolimus)	NCT00390195:Phase 1|Phase 2:Unknown status:Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, Chang JY, Whang-Peng J, Lin PW, Huang JD, Chen LT. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013 Jan;37(1):62-73. doi: 10.1111/apt.12132. Epub 2012 Nov 8.|Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247. Review.	html not right
perifosine	NCT00398814:Phase 1:Completed:Preliminary results / Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 16024	Html not right
floxuridine	NCT00410956:Phase 2:Active, not recruiting:Kemeny NE, Schwartz L, G nen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3-4):153-9. doi: 10.1159/000324704. Epub 2011 Jun 14.;;NCT00001576:Phase 1:Completed:No publish;;NCT00587067:Phase 2:Completed:No publish;;NCT01525069:Phase 1:Recruiting:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT03493061:Phase 2:Recruiting:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT00019760:Phase 2:Completed:No publish;;NCT00005860:Phase 1:Completed:No publish;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00004142:Phase 2:Completed:No publish;;NCT00063960:Phase 2:Completed:No publish;;NCT00002716:Phase 3:Completed:Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00003753:Phase 2:Completed:No publish;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00002842:Phase 2:Completed:No publish;;NCT00026234:Phase 2:Completed:No publish	Html not right
dexamethasone	NCT00410956:Phase 2:Active, not recruiting:Kemeny NE, Schwartz L, G nen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3-4):153-9. doi: 10.1159/000324704. Epub 2011 Jun 14.;;NCT01525069:Phase 1:Recruiting:No publish;;NCT00016380:Phase 3:Completed:National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006 Jul 20;24(21):3458-64.;;NCT02987907:Phase 3:Recruiting:No publish;;NCT03069950:Phase 2:Recruiting:No publish;;NCT00002716:Phase 3:Completed:Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00003753:Phase 2:Completed:No publish;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00026234:Phase 2:Completed:No publish	Html not right
darinaparsin	NCT00423306:Phase 2:Unknown status:No publish	html not right
sodium heparin	NCT00427310:Phase 3:Completed:O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010 Sep 1;28(25):3937-44. doi: 10.1200/JCO.2010.28.9538. Epub 2010 Aug 2.	html not right
thermodox	NCT00441376:Phase 1:Completed:No publish;;NCT00617981:Phase 3:Completed:No publish;;NCT02112656:Phase 3:Recruiting:No publish	html not right
thymopentin	NCT00460681:Phase 3:Unknown status:No publish	Html not right
capecitabine in hcc	NCT00464295:Phase 2:Completed:No publish	html not right
tegafur/uracil (ufur®)	NCT00464919:Phase 2:Completed:No publish	html not right
bevacizumab	NCT00467194:Phase 1:Completed:No publish;;NCT00576199:Phase 2:Completed:No publish;;NCT01180959:Phase 2:Active, not recruiting:No publish;;NCT00980239:Phase 1:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT03434379:Phase 3:Recruiting:No publish;;NCT03382886:Phase 1:Recruiting:No publish;;NCT00287222:Phase 2:Completed:No publish;;NCT00162669:Phase 2:Unknown status:No publish;;NCT00142467:Phase 2:Completed:No publish;;NCT01836653:Phase 2:Completed:No publish;;NCT01695772:Phase 4:Completed:No publish;;NCT01022541:Phase 2:Completed:No publish;;NCT02885753:Phase 3:Recruiting:No publish;;NCT01802645:Phase 2:Recruiting:No publish	Html not right
rapamycin	NCT00467194:Phase 1:Completed:No publish;;NCT02724332:Phase 1:Completed:No publish	Html not right
fluorouracil	NCT00471484:Phase 2:Unknown status:Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):159-65.;;NCT00003994:Phase 3:Completed:No publish;;NCT00507585:Phase 1:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT01775501:Phase 2:Active, not recruiting:No publish;;NCT00537121:Phase 1:Completed:No publish;;NCT00009893:Phase 2:Completed:Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1;103(1):111-8.;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT00019474:Phase 2:Unknown status:No publish;;NCT00654160:Phase 1:Completed:No publish;;NCT00019513:Phase 1:Completed:No publish;;NCT02042443:Phase 2:Completed:No publish;;NCT01643499:Phase 1:Active, not recruiting:No publish;;NCT00559455:Phase 2:Completed:No publish;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00438737:Phase 2:Unknown status:No publish;;NCT00002793:Phase 3:Unknown status:No publish;;NCT00006479:Phase 3:Unknown status:Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.;;NCT00002692:Phase 3:Unknown status:Current version of study NCT00002692 on ClinicalTrials.gov;;NCT00482222:Phase 3:Unknown status:No publish;;NCT00513266:Phase 2:Unknown status:No publish;;NCT00003834:Phase 2:Completed:Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.;;NCT00023868:Phase 3:Completed:No publish;;NCT03069950:Phase 2:Recruiting:No publish;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.;;NCT00544349:Phase 2:Completed:No publish;;NCT00002716:Phase 3:Completed:Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.;;NCT00557102:Phase 2:Completed:No publish;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00002842:Phase 2:Completed:No publish;;NCT00056030:Phase 2:Completed:No publish;;NCT00427310:Phase 3:Completed:O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010 Sep 1;28(25):3937-44. doi: 10.1200/JCO.2010.28.9538. Epub 2010 Aug 2.	html not right
oxaliplatin + 5-fluorouracil/leucovorin	NCT00471965:Phase 3:Completed:No publish	html not right
azd0530	NCT00475956:Phase 1:Completed:No publish	Html not right
capecitabine	NCT00483405:Phase 2:Completed:Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res. 2011 May;4(3):78-83.;;NCT00076609:Phase 1|Phase 2:Completed:No publish;;NCT00363584:Phase 3:Completed:No publish;;NCT02576964:Phase 2:Completed:No publish;;NCT00486356:Phase 1:Completed:No publish;;NCT00021047:Phase 1|Phase 2:Completed:No publish;;NCT02042443:Phase 2:Completed:No publish;;NCT00156975:Phase 3:Unknown status:No publish;;NCT00003867:Phase 1:Unknown status:Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.;;NCT00010023:Phase 1:Completed:Chen TT, Ryan T, Potmesil M, et al.: Cisplatin/capecitabine: tolerance and activity in patients with upper gastrointestinal cancers. [Abstract] American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 22-24 January 2004, San Francisco, CA. A-53, 2004.;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT00561522:Phase 2|Phase 3:Unknown status:No publish;;NCT03578874:Phase 2:Recruiting:No publish;;NCT03114085:Phase 2:Not yet recruiting:No publish;;NCT02716766:Phase 2:Recruiting:No publish;;NCT01167049:Phase 2:Unknown status:No publish;;NCT01022541:Phase 2:Completed:No publish;;NCT00482222:Phase 3:Unknown status:No publish;;NCT00026234:Phase 2:Completed:No publish	html not right
ngr-htnf	NCT00484211:Phase 2:Completed:Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer. 2010 Sep 7;103(6):837-44. doi: 10.1038/sj.bjc.6605858. Epub 2010 Aug 17.	html not right
sorafenib (bay-43-9006)	NCT00490685:Phase 2:Completed:No publish	html not right
octreotide-lar, lanreotide autogel	NCT00495846:Phase 2|Phase 3:Completed:Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V; Australasian Gastro-Intestinal Trials Group (AGITG) Ag0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer. 2006 Oct 9;95(7):853-61. Epub 2006 Sep 5. Erratum in: Br J Cancer. 2007 Apr 10;96(7):1154. Findlay, M [added]; Hargreaves, C [added]; Stockler, M [added]; Thompson, P [added]; Boyer, M [added]; Roberts, S [added]; Poon, A [added]; Scott, A M [added]; Kalff, V [added]; Garas, G [added]; Dowling, A [added]; Crawford, D [added]; Ring, J [added]; Ba.	html not right
zd6474 (zactima) 100mg	NCT00496509:Phase 1:Completed:No publish	html not right
zd6474 (zactima) 300mg	NCT00496509:Phase 1:Completed:No publish	html not right
azd2171	NCT00501605:Phase 1:Completed:No publish;;NCT00475956:Phase 1:Completed:No publish	html not right
avastin	NCT00507585:Phase 1:Completed:No publish	html not right
leucovorin	NCT00507585:Phase 1:Completed:No publish;;NCT00001576:Phase 1:Completed:No publish;;NCT01775501:Phase 2:Active, not recruiting:No publish;;NCT03493048:Phase 2:Recruiting:No publish;;NCT03500874:Phase 3:Recruiting:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT00559455:Phase 2:Completed:No publish;;NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.;;NCT01226719:Phase 2:Completed:No publish;;NCT00803647:Phase 2:Completed:No publish;;NCT03069950:Phase 2:Recruiting:No publish	html not right
vandetanib	NCT00508001:Phase 2:Completed:No publish	Html not right
s-adenosyl-l-methionine disulfate p-toluene-sulfonate	NCT00513461:Phase 2:Unknown status:No publish	html not right
rad001	NCT00516165:Phase 1|Phase 2:Completed:No publish	html not right
abt-869	NCT00517920:Phase 2:Completed:No publish	Html not right
tegafur/uracil	NCT00519688:Phase 2:Completed:No publish	html not right
opc-18	NCT00524498:Phase 2:Completed:No publish	html not right
abt-888	NCT00526617:Phase 1:Completed:Nuthalapati S, Munasinghe W, Giranda V, Xiong H. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clin Pharmacokinet. 2018 Jan;57(1):51-58. doi: 10.1007/s40262-017-0547-z.	Html not right
leucovorin calcium	NCT00537121:Phase 1:Completed:No publish;;NCT00009893:Phase 2:Completed:Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1;103(1):111-8.;;NCT00103298:Phase 2:Completed:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT00654160:Phase 1:Completed:No publish;;NCT00019513:Phase 1:Completed:No publish;;NCT02042443:Phase 2:Completed:No publish;;NCT01643499:Phase 1:Active, not recruiting:No publish;;NCT00019760:Phase 2:Completed:No publish;;NCT00005860:Phase 1:Completed:No publish;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00438737:Phase 2:Unknown status:No publish;;NCT00002793:Phase 3:Unknown status:No publish;;NCT00006479:Phase 3:Unknown status:Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.;;NCT00002692:Phase 3:Unknown status:Current version of study NCT00002692 on ClinicalTrials.gov;;NCT00482222:Phase 3:Unknown status:No publish;;NCT00513266:Phase 2:Unknown status:No publish;;NCT00003834:Phase 2:Completed:Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.;;NCT00023868:Phase 3:Completed:No publish;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.;;NCT00544349:Phase 2:Completed:No publish;;NCT00002716:Phase 3:Completed:Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.;;NCT00557102:Phase 2:Completed:No publish;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00002842:Phase 2:Completed:No publish;;NCT00056030:Phase 2:Completed:No publish	html not right
anastrozole	NCT00537771:Phase 4:Completed:No publish	Html not right
tamoxifen	NCT00537771:Phase 4:Completed:No publish	html not right
fentanyl sublingual spray	NCT00538850:Phase 3:Completed:Rauck R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M, Parikh N, Dillaha L. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012 May;28(5):859-70. doi: 10.1185/03007995.2012.683111. Epub 2012 May 2.	html not right
indocyanine green	NCT00540982:Phase 1|Phase 2:Completed:No publish	html not right
lidocaine	NCT00540982:Phase 1|Phase 2:Completed:No publish	Html not right
vinorelbine ditartrate	NCT00540982:Phase 1|Phase 2:Completed:No publish	html not right
endotag®-1	NCT00542048:Phase 2:Completed:No publish	html not right
lamivudine or entecavir	NCT00555334:Phase 4:Unknown status:No publish	html not right
nadolol	NCT00567216:Phase 4:Unknown status:No publish	Html not right
atropine	NCT00575523:Phase 4:Completed:No publish	html not right
selumetinib	NCT00604721:Phase 2:Completed:No publish;;NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	html not right
bevacizumab (avastin)	NCT00605722:Phase 2:Completed:No publish;;NCT00242502:Phase 2:Completed:No publish	html not right
erlotinib (tarceva)	NCT00605722:Phase 2:Completed:No publish;;NCT00901901:Phase 3:Completed:No publish	html not right
dasatinib	NCT00608361:Phase 1:Completed:No publish;;NCT02465060:Phase 2:Recruiting:No publish	Html not right
5% dextrose solution	NCT00617981:Phase 3:Completed:No publish	html not right
infusional 5-fluorouracil	NCT00619541:Phase 2:Completed:No publish	html not right
sorafenib (bay 43-9006)	NCT00619541:Phase 2:Completed:No publish	html not right
neoadjuvant chemotherapy with oxaliplatin and capecitabine	NCT00630045:Phase 3:Unknown status:No publish	html not right
pegylated interferon alpha 2a and plus ribavirin	NCT00630084:Phase 4:Completed:No publish	html not right
irinotecan plus capecitabine	NCT00635323:Phase 2:Completed:No publish	html not right
sodium thiosulfate	NCT00652132:Phase 3:Completed:No publish;;NCT00716976:Phase 3:Completed:No publish	html not right
neo-adjuvant treatment with bevacizumab	NCT00659022:Phase 2:Unknown status:No publish	html not right
neoadjuvant treatment with capecitabine and oxaliplatin	NCT00659022:Phase 2:Unknown status:No publish	html not right
neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin	NCT00659022:Phase 2:Unknown status:No publish	html not right
gm-csf	NCT00661622:Phase 2:Completed:No publish	html not right
bupropion hydrochloride	NCT00666978:Phase 4:Completed:No publish;;NCT00534001:Phase 2:Completed:No publish	html not right
pazopanib (gw786034)(gw786034)	NCT00674024:Phase 1:Completed:No publish	html not right
nexavar (sorafenib, bay43-9006)	NCT00692770:Phase 3:Completed:Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.	html not right
sorafenib and gemcitabine	NCT00703365:Phase 2:Completed:No publish	html not right
infusion of opioid growth factor	NCT00706576:Phase 1:Completed:No publish	html not right
ms-20	NCT00707681:Phase 2:Unknown status:No publish	html not right
lenalidomide	NCT00717756:Phase 2:Completed:Safran H, Charpentier KP, Kaubisch A, Mantripragada K, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng Y, Victor J, Plette A, Espat J, Bakalarski P, Wingate P, Berz D, Luppe D, Martel D, Rosati K, Aparo S. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. Am J Clin Oncol. 2015 Feb;38(1):1-4. doi: 10.1097/COC.0b013e3182868c66.;;NCT01545804:Phase 2:Completed:No publish	html not right
z-208	NCT00731445:Phase 1|Phase 2:Completed:No publish	html not right
hai abraxane	NCT00732836:Phase 1:Completed:No publish	html not right
iv abraxane	NCT00732836:Phase 1:Completed:No publish	html not right
disulfiram	NCT00742911:Phase 1:Completed:No publish	html not right
copper gluconate	NCT00742911:Phase 1:Completed:No publish	html not right
folfox6/cetuximab	NCT00743678:Phase 2:Completed:No publish	html not right
gc33	NCT00746317:Phase 1:Completed:No publish	html not right
sorafenib with capecitabine and oxaliplatin	NCT00752063:Phase 2:Unknown status:No publish	html not right
imatinib mesylate	NCT00764595:Phase 2:Completed:No publish;;NCT00025415:Phase 1:Completed:No publish	html not right
antiviral treatment (lamivudine or entecavir)	NCT00768157:Phase 4:Unknown status:No publish	html not right
everolimus, bevacizumab	NCT00775073:Phase 2:Completed:No publish	html not right
orantinib (tsu-68)	NCT00784290:Phase 1|Phase 2:Completed:No publish	html not right
sonovue-enhanced ultrasound	NCT00788697:Phase 3:Completed:No publish	html not right
cf102	NCT00790218:Phase 1|Phase 2:Completed:No publish;;NCT02128958:Phase 2:Recruiting:No publish	html not right
songyou	NCT00805896:Phase 2:Unknown status:No publish	html not right
sunitinib added to folfiri	NCT00806663:Phase 2:Completed:No publish	html not right
licartin (generic name,[131i]metuximab injection)	NCT00819650:Phase 2:Completed:No publish	html not right
epirubicin and lipiodol	NCT00820053:Phase 2:Completed:No publish	html not right
sorafenib + lbh589	NCT00823290:Phase 1:Unknown status:No publish	html not right
brivanib	NCT00825955:Phase 3:Completed:No publish;;NCT00437424:Phase 1:Completed:No publish;;NCT01540461:Phase 1:Completed:No publish;;NCT00908752:Phase 3:Completed:No publish;;NCT00858871:Phase 3:Completed:No publish	Html not right
lmwh	NCT00827554:Phase 2|Phase 3:Completed:No publish;;NCT02715492:Phase 3:Not yet recruiting:No publish	html not right
sonovue®	NCT00829413:Phase 3:Completed:No publish	html not right
licartin	NCT00829465:Phase 4:Completed:No publish	html not right
peginterferon alpha-2a and ribavirin	NCT00834860:Phase 4:Unknown status:No publish	html not right
epirubicin	NCT00843934:Phase 2|Phase 3:Unknown status:No publish;;NCT02631499:Phase 4:Not yet recruiting:No publish	html not right
adenosine	NCT00845689:Phase 1|Phase 2:Unknown status:No publish	html not right
yttrium-90 (y-90)	NCT00846131:Phase 1:Completed:Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014 Aug;61(2):309-17. doi: 10.1016/j.jhep.2014.03.023. Epub 2014 Mar 27.	html not right
chemotherapy with endostar	NCT00849264:Phase 2:Completed:No publish	html not right
treatment with cbp and 5-fu	NCT00849264:Phase 2:Completed:No publish	html not right
treatment with endostar, cbp and 5-fu	NCT00849264:Phase 2:Completed:No publish	html not right
iv cetuximab	NCT00852228:Phase 2:Unknown status:No publish	html not right
hai chronomodulated chemotherapy	NCT00852228:Phase 2:Unknown status:No publish	html not right
hai conventional chemotherapy	NCT00852228:Phase 2:Unknown status:No publish	html not right
irinotecan and on 01910.na	NCT00861783:Phase 1:Completed:Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.	html not right
oxaliplatin and on 01910.na	NCT00861783:Phase 1:Completed:Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.	html not right
adecatumumab	NCT00866944:Phase 2:Completed:No publish	html not right
adecatumumab and folfox	NCT00866944:Phase 2:Completed:No publish	html not right
folfox 4	NCT00866944:Phase 2:Completed:No publish	html not right
sorafenib tosylate	NCT00867321:Phase 1|Phase 2:Completed:No publish;;NCT01324076:Phase 3:Unknown status:No publish;;NCT01182272:Phase 2:Unknown status:No publish;;NCT01075113:Phase 1:Active, not recruiting:No publish;;NCT01005199:Phase 2:Completed:No publish;;NCT00881751:Phase 2:Completed:No publish;;NCT01011010:Phase 1:Completed:No publish;;NCT01075555:Phase 3:Completed:No publish;;NCT00941967:Phase 2:Unknown status:No publish;;NCT01497444:Phase 1:Active, not recruiting:No publish;;NCT01042041:Phase 1:Completed:No publish;;NCT01624285:Phase 2:Active, not recruiting:No publish;;NCT00844168:Phase 1:Completed:No publish;;NCT01008566:Phase 1:Completed:No publish;;NCT03211416:Phase 1|Phase 2:Recruiting:No publish;;NCT01666756:Phase 1:Active, not recruiting:No publish;;NCT01502410:Phase 2:Completed:No publish;;NCT01004978:Phase 3:Active, not recruiting:No publish;;NCT01015833:Phase 3:Active, not recruiting:No publish	html not right
amg 386	NCT00872014:Phase 2:Completed:No publish	html not right
tac + folfox4	NCT00874406:Phase 4:Unknown status:No publish	html not right
lc bead loaded with doxorubicin	NCT00877071:Phase 2:Completed:No publish	html not right
erlotinib hydrochloride	NCT00881751:Phase 2:Completed:No publish;;NCT00365391:Phase 2:Completed:No publish;;NCT00047346:Phase 1:Completed:No publish;;NCT02273362:Phase 1|Phase 2:Recruiting:No publish;;NCT00987766:Phase 1:Completed:No publish;;NCT00033462:Phase 2:Completed:No publish;;NCT00397384:Phase 1:Completed:No publish;;NCT00030498:Phase 1:Completed:No publish	html not right
aln-vsp02	NCT00882180:Phase 1:Completed:No publish	html not right
aeg35156 antisense iv infusion	NCT00882869:Phase 1|Phase 2:Completed:No publish	html not right
[f-18] vm4-037	NCT00884520:Early Phase 1:Completed:No publish	html not right
panitumumab+folfox-4	NCT00885885:Phase 2:Completed:No publish	html not right
panitumumab+folfiri	NCT00885885:Phase 2:Completed:No publish	html not right
foretinib	NCT00920192:Phase 1:Completed:No publish	html not right
fostamatinib disodium	NCT00923481:Phase 2:Completed:No publish	html not right
sorafenib, cisplatin, fluorouracil	NCT00933816:Phase 1|Phase 2:Completed:No publish	html not right
gemcitabine hydrochloride	NCT00941967:Phase 2:Unknown status:No publish;;NCT00006010:Phase 2:Completed:Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct;35(5):418-23.;;NCT00304135:Phase 2|Phase 3:Completed:Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F��d��ration Francophone de Canc��rologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.;;NCT00059865:Phase 1|Phase 2:Completed:Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer. 2007;38(2-4):87-94. doi: 10.1007/s12029-008-9037-8. Epub 2008 Nov 21.;;NCT00009893:Phase 2:Completed:Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1;103(1):111-8.;;NCT01313377:Phase 3:Completed:No publish;;NCT00987766:Phase 1:Completed:No publish;;NCT00019513:Phase 1:Completed:No publish	html not right
oxaliplatin	NCT00941967:Phase 2:Unknown status:No publish;;NCT00483405:Phase 2:Completed:Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res. 2011 May;4(3):78-83.;;NCT00471484:Phase 2:Unknown status:Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):159-65.;;NCT00052364:Phase 2:Completed:No publish;;NCT00507585:Phase 1:Completed:No publish;;NCT00980239:Phase 1:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT01775501:Phase 2:Active, not recruiting:No publish;;NCT00304135:Phase 2|Phase 3:Completed:Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F��d��ration Francophone de Canc��rologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.;;NCT01525069:Phase 1:Recruiting:No publish;;NCT01313377:Phase 3:Completed:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00987766:Phase 1:Completed:No publish;;NCT00003427:Phase 1:Completed:Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.;;NCT01042691:Phase 1:Completed:No publish;;NCT01643499:Phase 1:Active, not recruiting:No publish;;NCT03493048:Phase 2:Recruiting:No publish;;NCT03493061:Phase 2:Recruiting:No publish;;NCT01511146:Phase 2:Unknown status:No publish;;NCT01384994:Phase 2:Unknown status:No publish;;NCT03500874:Phase 3:Recruiting:No publish;;NCT01959061:Phase 4:Recruiting:No publish;;NCT00557557:Phase 1:Completed:No publish;;NCT00101270:Phase 1:Completed:No publish;;NCT00091182:Phase 2:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT01348412:Phase 2:Completed:No publish;;NCT00156975:Phase 3:Unknown status:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT00274885:Phase 4:Unknown status:No publish;;NCT00005860:Phase 1:Completed:No publish;;NCT02129322:Phase 2:Not yet recruiting:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT03578874:Phase 2:Recruiting:No publish;;NCT02716766:Phase 2:Recruiting:No publish;;NCT02426450:Phase 2:Unknown status:No publish;;NCT00559455:Phase 2:Completed:No publish;;NCT00280618:Phase 2:Completed:No publish;;NCT00142467:Phase 2:Completed:No publish;;NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00438737:Phase 2:Unknown status:No publish;;NCT01226719:Phase 2:Completed:No publish;;NCT00803647:Phase 2:Completed:No publish;;NCT00005077:Phase 1:Completed:No publish;;NCT00006479:Phase 3:Unknown status:Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.;;NCT01022541:Phase 2:Completed:No publish;;NCT00482222:Phase 3:Unknown status:No publish;;NCT00513266:Phase 2:Unknown status:No publish;;NCT00003834:Phase 2:Completed:Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.;;NCT00006062:Phase 1:Completed:No publish;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.;;NCT01802645:Phase 2:Recruiting:No publish;;NCT00544349:Phase 2:Completed:No publish;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00026234:Phase 2:Completed:No publish;;NCT00056030:Phase 2:Completed:No publish	html not right
4sc-201	NCT00943449:Phase 2:Completed:No publish	html not right
e7080	NCT00946153:Phase 1|Phase 2:Completed:No publish	No target
sorafenib tosylate, hace : doxorubicin hydrochloride and mitomycin c	NCT00949182:Phase 2:Completed:No publish	html not right
biib022	NCT00956436:Phase 1:Completed:No publish	html not right
adefovir	NCT00960518:Phase 2:Unknown status:No publish	html not right
combretastatin a1 diphosphate (oxi4503)	NCT00960557:Phase 1:Completed:No publish	html not right
gc33(ro5137382)	NCT00976170:Phase 1:Completed:No publish	html not right
cetuximab	NCT00980239:Phase 1:Completed:No publish;;NCT01564810:Phase 4:Unknown status:No publish;;NCT00397384:Phase 1:Completed:No publish;;NCT03493048:Phase 2:Recruiting:No publish;;NCT00153998:Phase 2:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT03319459:Phase 1:Recruiting:No publish;;NCT00142428:Phase 2:Completed:No publish;;NCT01836653:Phase 2:Completed:No publish;;NCT01802645:Phase 2:Recruiting:No publish	No target
irinotecan	NCT00980239:Phase 1:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT03493048:Phase 2:Recruiting:No publish;;NCT03493061:Phase 2:Recruiting:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.;;NCT01226719:Phase 2:Completed:No publish;;NCT01802645:Phase 2:Recruiting:No publish;;NCT00037804:Phase 1:Completed:No publish	html not right
temsirolimus	NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT01010126:Phase 2:Completed:No publish;;NCT01687673:Phase 2:Active, not recruiting:No publish;;NCT01567930:Phase 2:Unknown status:No publish	No target
pv-10 (10% rose bengal disodium)	NCT00986661:Phase 1:Recruiting:No publish	html not right
capecitabine plus oxaliplatin	NCT00997685:Phase 2:Unknown status:No publish	html not right
azd8055	NCT00999882:Phase 1:Completed:No publish	No target
bay73-4506	NCT01003015:Phase 2:Completed:Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25.	html not right
bibf 1120	NCT01004003:Phase 2:Completed:No publish;;NCT00987935:Phase 2:Completed:No publish	html not right
everolimus	NCT01005199:Phase 2:Completed:No publish;;NCT01642186:Phase 2:Active, not recruiting:No publish;;NCT02081755:Phase 4:Recruiting:No publish;;NCT01423708:Phase 2:Unknown status:No publish;;NCT01469572:Phase 1:Active, not recruiting:No publish;;NCT01488487:Phase 2:Completed:No publish;;NCT01035229:Phase 3:Completed:No publish	html not right
sorafenib with temsirolimus	NCT01008917:Phase 1:Completed:No publish	html not right
mitomycin c	NCT01011010:Phase 1:Completed:No publish;;NCT01042041:Phase 1:Completed:No publish;;NCT00023868:Phase 3:Completed:No publish	html not right
cs-1008	NCT01033240:Phase 2:Completed:No publish	html not right
everolimus placebo	NCT01035229:Phase 3:Completed:No publish	html not right
foflox4	NCT01035385:Phase 3:Unknown status:No publish	html not right
idarubicin	NCT01040559:Phase 1:Completed:No publish	No target
fluorouracil implants	NCT01055743:Phase 2:Unknown status:No publish	html not right
eicosapentaenoic acid free fatty acid	NCT01070355:Phase 2:Completed:No publish	html not right
vorinostat	NCT01075113:Phase 1:Active, not recruiting:No publish;;NCT00537121:Phase 1:Completed:No publish	html not right
[f 18]hx4	NCT01075399:Phase 2:Completed:No publish	html not right
pravastatin sodium	NCT01075555:Phase 3:Completed:No publish	html not right
adjuvant group	NCT01088581:Phase 3:Completed:No publish	html not right
sorafenib (nexavar, bay43-9006) sorafenib (nexavar, bay43-9006) + nerison fatty ointment sorafenib (nexavar, bay43-9006)+neribas fatty ointment	NCT01098760:Phase 4:Completed:No publish	html not right
telbivudine	NCT01102335:Phase 4:Unknown status:No publish	html not right
doxorubicin, superabsorbent polymer microspheres, embolotherapy	NCT01116635:Phase 1|Phase 2:Completed:No publish	html not right
ezn-2968	NCT01120288:Phase 1:Completed:No publish	html not right
188re-sss lipiodol	NCT01126463:Phase 1:Recruiting:No publish	html not right
silybin	NCT01129570:Phase 1:Completed:No publish	html not right
sorafenib, ts-1	NCT01131689:Phase 1:Completed:No publish	html not right
pentoxifylline	NCT01149304:Phase 2:Completed:Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One. 2014 Nov 13;9(11):e112731. doi: 10.1371/journal.pone.0112731. eCollection 2014.	html not right
ursodeoxycholic acid	NCT01149304:Phase 2:Completed:Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One. 2014 Nov 13;9(11):e112731. doi: 10.1371/journal.pone.0112731. eCollection 2014.	html not right
enoxaparin	NCT01149304:Phase 2:Completed:Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One. 2014 Nov 13;9(11):e112731. doi: 10.1371/journal.pone.0112731. eCollection 2014.	html not right
sunitinib malate	NCT01164202:Phase 2|Phase 3:Completed:No publish;;NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kov��cs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.;;NCT02465060:Phase 2:Recruiting:No publish	html not right
placebo	NCT01164202:Phase 2|Phase 3:Completed:No publish;;NCT02029157:Phase 3:Completed:No publish;;NCT00845689:Phase 1|Phase 2:Unknown status:No publish;;NCT01640808:Phase 3:Unknown status:No publish;;NCT00575523:Phase 4:Completed:No publish;;NCT01562821:Phase 2:Completed:Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, Nivatvongs S, Lee PH. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg. 2006 Feb;191(2):245-9.;;NCT02435433:Phase 3:Recruiting:No publish;;NCT00105443:Phase 3:Completed:Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.;;NCT00707681:Phase 2:Unknown status:No publish;;NCT00494299:Phase 3:Completed:Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.;;NCT00692770:Phase 3:Completed:Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.;;NCT00538850:Phase 3:Completed:Rauck R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M, Parikh N, Dillaha L. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012 May;28(5):859-70. doi: 10.1185/03007995.2012.683111. Epub 2012 May 2.;;NCT03062358:Phase 3:Recruiting:No publish;;NCT02702401:Phase 3:Active, not recruiting:No publish;;NCT02528643:Phase 2:Active, not recruiting:No publish;;NCT02329860:Phase 3:Active, not recruiting:No publish;;NCT02178358:Phase 2:Active, not recruiting:No publish;;NCT02128958:Phase 2:Recruiting:No publish;;NCT01774344:Phase 3:Active, not recruiting:Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.;;NCT01755767:Phase 3:Completed:No publish;;NCT01507168:Phase 2:Completed:No publish;;NCT00080236:Phase 2:Completed:No publish;;NCT01287585:Phase 3:Completed:No publish;;NCT01258608:Phase 2:Completed:No publish;;NCT00988741:Phase 2:Completed:No publish;;NCT00901901:Phase 3:Completed:No publish;;NCT01265576:Phase 2:Unknown status:No publish;;NCT00858871:Phase 3:Completed:No publish;;NCT00855218:Phase 2:Completed:No publish;;NCT00805896:Phase 2:Unknown status:No publish;;NCT00492752:Phase 3:Completed:Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.;;NCT01070355:Phase 2:Completed:No publish	html not right
jx-594 followed by sorafenib	NCT01171651:Phase 2:Completed:No publish	html not right
cudc-101	NCT01171924:Phase 1:Completed:No publish	No target
cc-223	NCT01177397:Phase 1|Phase 2:Completed:No publish	No target
maa for diagnostic spect imaging	NCT01186263:Phase 2:Completed:No publish	html not right
diagnostic b20- spect imaging.	NCT01186263:Phase 2:Completed:No publish	html not right
sorafenib standard dosing regimen	NCT01203787:Phase 4:Completed:No publish	html not right
sorafenib ramp-up regimen	NCT01203787:Phase 4:Completed:No publish	html not right
bay86-9766 mek inhibitor + sorafenib	NCT01204177:Phase 2:Completed:No publish	html not right
[f-18] fmiso	NCT01213030:Phase 1|Phase 2:Completed:No publish	html not right
[f-18] hx4	NCT01213030:Phase 1|Phase 2:Completed:No publish	html not right
sorafenib with low-dose fp	NCT01214343:Phase 3:Unknown status:No publish	html not right
tace with sorafenib	NCT01217034:Phase 2:Active, not recruiting:No publish	html not right
dovitinib	NCT01232296:Phase 2:Completed:No publish	No target
cinobufacin injection	NCT01236690:Phase 2:Unknown status:No publish	html not right
torisel	NCT01251458:Phase 1|Phase 2:Completed:No publish	html not right
mapatumumab	NCT01258608:Phase 2:Completed:No publish	html not right
sorafenib and zoledronic acid	NCT01259193:Phase 2:Unknown status:No publish	html not right
panitumumab, oxaliplatin, 5-fu	NCT01260415:Phase 2:Completed:No publish	html not right
clevudine, adefovir	NCT01263002:Phase 4:Completed:No publish	html not right
bavituximab and sorafenib	NCT01264705:Phase 1|Phase 2:Unknown status:No publish	html not right
vt-122 (propranolol plus etodolac)	NCT01265576:Phase 2:Unknown status:No publish	html not right
ag-013736	NCT01273662:Phase 2:Completed:No publish	html not right
adi-peg 20 (arginine deiminase formulated with polyethylene glycol)	NCT01287585:Phase 3:Completed:No publish	html not right
propranolol	NCT01298284:Phase 4:Unknown status:No publish;;NCT01970748:Phase 4:Unknown status:No publish;;NCT01451658:Phase 4:Unknown status:No publish	html not right
trc 105	NCT01306058:Phase 1|Phase 2:Completed:No publish	html not right
chemotherapy ± targeted therapy	NCT01307878:Phase 4:Unknown status:No publish	html not right
sb injection	NCT01308645:Phase 2:Unknown status:No publish	html not right
ro5323441	NCT01308723:Phase 1:Completed:No publish	html not right
cetuximab; mfolfox6	NCT01322178:Phase 2:Unknown status:No publish	html not right
doxorubicin-eluting beads	NCT01324076:Phase 3:Unknown status:No publish;;NCT01004978:Phase 3:Active, not recruiting:No publish	html not right
axitinib (ag-013736)	NCT01334112:Phase 2:Active, not recruiting:No publish;;NCT03289533:Phase 1:Recruiting:No publish	html not right
paclitaxel , carboplatin, endostatin	NCT01347424:Phase 2:Unknown status:No publish	html not right
paclitaxel and carboplatin	NCT01347424:Phase 2:Unknown status:No publish	html not right
dendritic cells vaccine	NCT01348256:Phase 2:Recruiting:No publish	html not right
other intravenous chemotherapy drugs	NCT01348412:Phase 2:Completed:No publish	html not right
axitinib	NCT01352728:Phase 2:Completed:No publish	No target
pd-0332991	NCT01356628:Phase 2:Active, not recruiting:No publish	No target
pravastatin	NCT01357486:Phase 2:Completed:No publish;;NCT01418729:Phase 2:Completed:No publish	html not right
m-tor inhibitor free	NCT01374750:Phase 2:Completed:No publish	html not right
trc105	NCT01375569:Phase 2:Completed:No publish;;NCT02560779:Phase 1|Phase 2:Recruiting:No publish	html not right
11c-choline	NCT01377220:Phase 2:Unknown status:No publish	html not right
tace-deb	NCT01381211:Phase 2:Unknown status:No publish	html not right
90y-re	NCT01381211:Phase 2:Unknown status:No publish	html not right
folic acid	NCT01384994:Phase 2:Unknown status:No publish	html not right
5-fu	NCT01384994:Phase 2:Unknown status:No publish;;NCT00557557:Phase 1:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT01836653:Phase 2:Completed:No publish;;NCT00803647:Phase 2:Completed:No publish;;NCT01802645:Phase 2:Recruiting:No publish	html not right
panitumumab	NCT01384994:Phase 2:Unknown status:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT01226719:Phase 2:Completed:No publish;;NCT02885753:Phase 3:Recruiting:No publish;;NCT03069950:Phase 2:Recruiting:No publish	html not right
oxaliplatin, capecitabine, trastuzumab	NCT01387295:Phase 2:Unknown status:No publish;;NCT01387373:Phase 2:Unknown status:No publish	html not right
n-acetylcystein	NCT01394497:Phase 2:Completed:D'Amico F, Vitale A, Piovan D, Bertacco A, Ramirez Morales R, Chiara Frigo A, Bassi D, Bonsignore P, Gringeri E, Valmasoni M, Garbo G, Lodo E, D'Amico FE, Scopelliti M, Carraro A, Gambato M, Brolese A, Zanus G, Neri D, Cillo U. Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl. 2013 Feb;19(2):135-44. doi: 10.1002/lt.23527. Epub 2012 Sep 26.	html not right
18f-fluoromethylcholine	NCT01395030:Phase 2:Active, not recruiting:No publish	html not right
opb-31121	NCT01406574:Phase 1|Phase 2:Completed:No publish	html not right
opb-31121 phase2	NCT01406574:Phase 1|Phase 2:Completed:No publish	html not right
nhs-il-12	NCT01417546:Phase 1:Recruiting:No publish	html not right
akt inhibitor mk2206	NCT01425879:Phase 2:Completed:No publish	html not right
sox	NCT01429961:Phase 2:Unknown status:No publish	html not right
oral	NCT01438450:Phase 2|Phase 3:Unknown status:No publish	html not right
folinic acid	NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT02885753:Phase 3:Recruiting:No publish;;NCT01802645:Phase 2:Recruiting:No publish	html not right
trabectedin (ecteinascidin-743, et-743, yondelis [r])	NCT01453283:Phase 1:Completed:No publish	html not right
177lu-dota-tate	NCT01456078:Phase 2:Recruiting:No publish	html not right
pasireotide	NCT01469572:Phase 1:Active, not recruiting:No publish;;NCT01488487:Phase 2:Completed:No publish	html not right
sir-sphere	NCT01482442:Phase 3:Completed:No publish	html not right
tyroserleutide for injection ,chemotherapy(mitomycin, and fluorouracil )	NCT01489566:Phase 3:Unknown status:No publish	html not right
the placebo ,chemotherapy(mitomycin, and fluorouracil )	NCT01489566:Phase 3:Unknown status:No publish	html not right
hypoxia-activated prodrug th-302	NCT01497444:Phase 1:Active, not recruiting:No publish	html not right
medi-573 (1 of 3 doses)	NCT01498952:Phase 1:Completed:No publish	html not right
ro5137382	NCT01507168:Phase 2:Completed:No publish	html not right
mitomycin + gemcitabine	NCT01511146:Phase 2:Unknown status:No publish	html not right
s-1 combined with leucovorin	NCT01533324:Phase 2:Unknown status:No publish	html not right
activated recombinant human factor vii	NCT01562821:Phase 2:Completed:Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, Nivatvongs S, Lee PH. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg. 2006 Feb;191(2):245-9.	html not right
chemotherapy of mfolfox6 or folfiri	NCT01564810:Phase 4:Unknown status:No publish	html not right
gadoxetic acid	NCT01575574:Phase 4:Completed:No publish	html not right
nintedanib high dose	NCT01594125:Phase 1:Completed:No publish	html not right
nintedanib low dose	NCT01594125:Phase 1:Completed:No publish	html not right
nintedanib medium dose	NCT01594125:Phase 1:Completed:No publish	html not right
sorafenib combined with tace	NCT01605734:Phase 2:Unknown status:No publish	html not right
immu-132	NCT01631552:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
bevacizumab, mfolfox, folfiri	NCT01632722:Phase 2:Completed:No publish	html not right
romidepsin	NCT01638533:Phase 1:Recruiting:No publish	html not right
xenetix-ct perfusion imaging	NCT01639703:Phase 4:Completed:No publish	html not right
nik-333(peretinoin)	NCT01640808:Phase 3:Unknown status:No publish	html not right
letrozole plus leuprolide	NCT01642186:Phase 2:Active, not recruiting:No publish	html not right
combination of everolimus, letrozole and leuprolide	NCT01642186:Phase 2:Active, not recruiting:No publish	html not right
tranexamic acid	NCT01655641:Phase 2|Phase 3:Unknown status:Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007 May 31;356(22):2301-11. Review.	html not right
best standard of care	NCT01655693:Phase 3:Active, not recruiting:No publish	html not right
arq 197	NCT01656265:Phase 1:Completed:No publish;;NCT00988741:Phase 2:Completed:No publish;;NCT00802555:Phase 1:Completed:No publish	html not right
ipilimumab	NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT03203304:Phase 1:Recruiting:No publish;;NCT03222076:Phase 2:Recruiting:No publish	No target
cabozantinib	NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT03299946:Phase 1:Recruiting:No publish;;NCT03539822:Phase 1:Not yet recruiting:No publish;;NCT03586973:Phase 2:Recruiting:No publish	html not right
sta-9090	NCT01665937:Phase 1:Completed:No publish	html not right
interferon-alpha (ifn-alpha)	NCT01681446:Phase 3:Recruiting:No publish	html not right
sorafenib:	NCT01687673:Phase 2:Active, not recruiting:No publish	html not right
5-fu based doublet chemotherapy	NCT01695772:Phase 4:Completed:No publish	html not right
huachansu	NCT01715532:Phase 2:Unknown status:No publish	html not right
phase i dose level -1	NCT01721941:Phase 1:Unknown status:No publish	html not right
phase i dose level 1	NCT01721941:Phase 1:Unknown status:No publish	html not right
phase i dose level 2	NCT01721941:Phase 1:Unknown status:No publish	html not right
phase i dose level 3	NCT01721941:Phase 1:Unknown status:No publish	html not right
mm-141	NCT01733004:Phase 1:Completed:No publish	html not right
tasquinimod	NCT01743469:Phase 2:Completed:No publish	No target
suranix	NCT01747642:Phase 2|Phase 3:Unknown status:No publish	html not right
sgi-110	NCT01752933:Phase 2:Completed:No publish	html not right
ascorbic acid + sorafenib	NCT01754987:Phase 1|Phase 2:Completed:No publish	html not right
tivantinib	NCT01755767:Phase 3:Completed:No publish	html not right
bevacizumab plus chemotherapy	NCT01763450:Phase 2:Unknown status:No publish	html not right
6,8-bis(benzylthio)octanoic acid	NCT01766219:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
huaier granule	NCT01770431:Phase 4:Completed:No publish	html not right
regorafenib (bay73-4506)	NCT01774344:Phase 3:Active, not recruiting:Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.	html not right
g-202	NCT01777594:Phase 2:Completed:No publish	html not right
chlorhexidine gluconate	NCT01782573:Phase 4:Completed:No publish	html not right
0.9% sodium chloride	NCT01782573:Phase 4:Completed:No publish	html not right
meglumine gadoterate	NCT01806740:Phase 4:Active, not recruiting:No publish	html not right
mct/lct and fish oil	NCT01819961:Phase 4:Unknown status:No publish	html not right
mct/lct	NCT01819961:Phase 4:Unknown status:No publish	html not right
interferon alfa、fluorouracil	NCT01834963:Phase 2:Recruiting:No publish	html not right
cisplatin、fluorouracil	NCT01834963:Phase 2:Recruiting:No publish	html not right
tivozanib	NCT01835223:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
l-ohp	NCT01836653:Phase 2:Completed:No publish	html not right
l-lv	NCT01836653:Phase 2:Completed:No publish	html not right
azd9150	NCT01839604:Phase 1:Completed:No publish	html not right
hia debiri + systemic folfox	NCT01839877:Phase 2:Active, not recruiting:No publish	html not right
tremelimumab	NCT01853618:Phase 1:Active, not recruiting:No publish;;NCT02754856:Phase 1:Recruiting:No publish	html not right
recombinant human adenovirus type 5 injection	NCT01869088:Phase 3:Active, not recruiting:Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, Neuhaus P, Felix R. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000 Feb;214(2):349-57.	html not right
lipiodol	NCT01877187:Phase 2:Active, not recruiting:No publish;;NCT01959061:Phase 4:Recruiting:No publish;;NCT02638857:Phase 1|Phase 2:Unknown status:No publish;;NCT02755311:Phase 3:Unknown status:No publish;;NCT02631499:Phase 4:Not yet recruiting:No publish	html not right
lamivudine 100mg once daily; or entecavir 0.5mg once daily.	NCT01894269:Phase 4:Unknown status:No publish	html not right
onartuzumab	NCT01897038:Phase 1:Completed:No publish	html not right
immuncell-lc	NCT01897610:Phase 2:Completed:No publish	html not right
sorafenib + pravastatin	NCT01903694:Phase 3:Completed:No publish;;NCT01357486:Phase 2:Completed:No publish	html not right
cabozantinib tablets	NCT01908426:Phase 3:Active, not recruiting:No publish	html not right
placebo tablets	NCT01908426:Phase 3:Active, not recruiting:No publish	html not right
ixazomib	NCT01912222:Phase 1:Completed:No publish	html not right
refametinib (bay86-9766)	NCT01915589:Phase 2:Completed:No publish;;NCT01915602:Phase 2:Completed:No publish	html not right
sorafenib (bay43-9006)	NCT01915602:Phase 2:Completed:No publish	html not right
urea-based cream	NCT01934829:Phase 2:Completed:Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005 May;9(2):191-211, v. Review.	html not right
colchicine	NCT01935700:Phase 2:Recruiting:No publish	No target
aspirin	NCT01936233:Phase 3:Unknown status:No publish	html not right
lamivudine	NCT01936233:Phase 3:Unknown status:No publish;;NCT02650271:Phase 2|Phase 3:Recruiting:Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013 Sep;10(3):158-64. doi: 10.7497/j.issn.2095-3941.2013.03.006.	html not right
neratinib	NCT01953926:Phase 2:Recruiting:No publish	html not right
fulvestrant	NCT01953926:Phase 2:Recruiting:No publish	No target
raltitrexed	NCT01959061:Phase 4:Recruiting:No publish;;NCT01348412:Phase 2:Completed:No publish	No target
oxaliplatin;capecitabine	NCT01962376:Phase 4:Unknown status:No publish	html not right
oxaliplatin;capecitabine;bevacizumab	NCT01962376:Phase 4:Unknown status:No publish	html not right
ethiodized oil + doxorubicin	NCT01966133:Phase 3:Active, not recruiting:No publish	html not right
aldesleukin	NCT01967823:Phase 2:Recruiting:No publish;;NCT01174121:Phase 2:Recruiting:No publish	html not right
fludarabine	NCT01967823:Phase 2:Recruiting:No publish;;NCT03084380:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT01174121:Phase 2:Recruiting:No publish;;NCT02905188:Phase 1:Not yet recruiting:No publish	html not right
5-fu and oxaliplatin	NCT01972503:Phase 4:Unknown status:No publish	html not right
hcq	NCT02013778:Phase 1|Phase 2:Recruiting:No publish	html not right
bevacizumab [avastin]	NCT02013830:Phase 2:Completed:No publish	html not right
capecitabine [xeloda]	NCT02013830:Phase 2:Completed:No publish	html not right
lapatinib	NCT02015169:Phase 2:Completed:No publish	No target
tace containing as2o3	NCT02018757:Phase 2:Unknown status:No publish	html not right
tace containing placebo	NCT02018757:Phase 2:Unknown status:No publish	html not right
dalantercept plus sorafenib	NCT02024087:Phase 1|Phase 2:Completed:No publish	html not right
zavedos®	NCT02028949:Phase 1:Completed:No publish	html not right
arq197	NCT02029157:Phase 3:Completed:No publish	html not right
dexmedetomidine	NCT02044224:Phase 4:Completed:No publish;;NCT02016391:Phase 4:Completed:No publish	No target
folfoxiri + cetuximab	NCT02063529:Phase 2:Recruiting:No publish	html not right
folfoxiri	NCT02063529:Phase 2:Recruiting:No publish;;NCT02350530:Phase 2:Recruiting:No publish;;NCT03487939:Phase 2:Not yet recruiting:No publish	html not right
omp-54f28 with sorafenib	NCT02069145:Phase 1:Completed:No publish	html not right
18f- fluorocholine	NCT02074202:Phase 3:Unknown status:No publish	html not right
18f- fluorodeoxyglucose	NCT02074202:Phase 3:Unknown status:No publish	html not right
tacrolimus	NCT02081755:Phase 4:Recruiting:No publish	html not right
myfortic	NCT02081755:Phase 4:Recruiting:No publish	html not right
cellcept	NCT02081755:Phase 4:Recruiting:No publish	html not right
imuran	NCT02081755:Phase 4:Recruiting:No publish	html not right
ly2875358	NCT02082210:Phase 1|Phase 2:Completed:No publish	html not right
capecitabine, oxaliplatin, irinotecan and bevacizumab	NCT02086656:Phase 2:Active, not recruiting:No publish	html not right
n-acetylcysteine	NCT02094625:Phase 1:Recruiting:No publish	html not right
adi-peg 20	NCT02101593:Phase 1:Completed:No publish;;NCT02006030:Phase 2:Completed:No publish;;NCT02102022:Phase 1|Phase 2:Recruiting:No publish;;NCT02029690:Phase 1:Active, not recruiting:No publish;;NCT00056992:Phase 2:Completed:No publish	html not right
hai	NCT02102789:Phase 3:Recruiting:No publish	html not right
dummy infusion	NCT02112656:Phase 3:Recruiting:No publish	html not right
msc2156119j	NCT02115373:Phase 1|Phase 2:Completed:No publish;;NCT01988493:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
s-1	NCT02129322:Phase 2:Not yet recruiting:No publish;;NCT01997957:Phase 4:Unknown status:No publish;;NCT02634502:Phase 2:Recruiting:No publish	html not right
metformin xr	NCT02145559:Phase 1:Active, not recruiting:No publish	html not right
delayed metformin	NCT02145559:Phase 1:Active, not recruiting:No publish	html not right
sirolimus	NCT02145559:Phase 1:Active, not recruiting:No publish;;NCT00328770:Phase 2|Phase 3:Completed:No publish;;NCT01522820:Phase 1:Completed:No publish;;NCT01374750:Phase 2:Completed:No publish;;NCT00355862:Phase 3:Completed:No publish;;NCT00554125:Phase 3:Unknown status:No publish	html not right
lde225	NCT02151864:Phase 1:Active, not recruiting:No publish	html not right
folfox/ folfiri with bevacizumab	NCT02162563:Phase 3:Recruiting:No publish	html not right
folfoxiri with bevacizumab	NCT02162563:Phase 3:Recruiting:No publish	html not right
folfox/ folfiri with panitumumab	NCT02162563:Phase 3:Recruiting:No publish	html not right
vitamin d3	NCT02172651:Early Phase 1:Recruiting:No publish;;NCT02779465:Phase 4:Not yet recruiting:Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.	html not right
tirapazamine	NCT02174549:Phase 1|Phase 2:Recruiting:No publish;;NCT03145558:Phase 2:Recruiting:No publish	html not right
sevoflurane	NCT02174575:Phase 4:Unknown status:No publish	html not right
desflurane	NCT02174575:Phase 4:Unknown status:No publish	html not right
mk-3475	NCT02178722:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
incb024360	NCT02178722:Phase 1|Phase 2:Active, not recruiting:No publish	No target
lyso-thermosensitive liposomal (ltsl) doxorubicin	NCT02181075:Phase 1:Completed:No publish	html not right
tkm-080301	NCT02191878:Phase 1|Phase 2:Completed:No publish;;NCT01437007:Phase 1:Completed:No publish	html not right
ganciclovir	NCT02202564:Phase 2:Completed:No publish	No target
adv-tk	NCT02202564:Phase 2:Completed:No publish;;NCT03313596:Phase 3:Recruiting:No publish	html not right
peprostat	NCT02204930:Phase 1:Completed:No publish	html not right
oral pentamidine	NCT02210182:Phase 1:Completed:No publish	html not right
donafenib(200mg)	NCT02229071:Phase 1|Phase 2:Completed:No publish	html not right
donafenib(300mg)	NCT02229071:Phase 1|Phase 2:Completed:No publish	html not right
enmd-2076	NCT02234986:Phase 2:Active, not recruiting:No publish	No target
ly2157299	NCT02240433:Phase 1:Active, not recruiting:No publish;;NCT02178358:Phase 2:Active, not recruiting:No publish;;NCT01246986:Phase 2:Active, not recruiting:No publish	No target
oral chemotherapy	NCT02240771:Phase 2|Phase 3:Unknown status:No publish	html not right
cidan capsule	NCT02253511:Phase 4:Unknown status:No publish	html not right
stm 434	NCT02262455:Phase 1:Completed:No publish	html not right
liposomal doxorubicin	NCT02262455:Phase 1:Completed:No publish;;NCT00507962:Phase 1:Completed:No publish	html not right
bbi503	NCT02279719:Phase 1|Phase 2:Recruiting:No publish;;NCT02354898:Phase 1:Recruiting:No publish;;NCT02232633:Phase 2:Active, not recruiting:No publish	html not right
bbi608	NCT02279719:Phase 1|Phase 2:Recruiting:No publish;;NCT02358395:Phase 1:Completed:No publish	html not right
thymalfasin	NCT02281266:Phase 4:Not yet recruiting:No publish	html not right
nucleoside analog (suggest to use entecavir)	NCT02281266:Phase 4:Not yet recruiting:No publish	html not right
sorafenib	NCT02292173:Phase 1:Recruiting:No publish;;NCT00875615:Phase 2:Completed:No publish;;NCT00997022:Phase 1:Completed:No publish;;NCT01754987:Phase 1|Phase 2:Completed:No publish;;NCT00813293:Phase 2:Active, not recruiting:No publish;;NCT01932385:Phase 2|Phase 3:Completed:No publish;;NCT01033240:Phase 2:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT01775501:Phase 2:Active, not recruiting:No publish;;NCT01306058:Phase 1|Phase 2:Completed:No publish;;NCT02575339:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT00844883:Phase 2:Completed:No publish;;NCT00999843:Phase 1|Phase 2:Unknown status:No publish;;NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT03439891:Phase 2:Recruiting:No publish;;NCT00976170:Phase 1:Completed:No publish;;NCT00906373:Phase 2:Completed:No publish;;NCT02240433:Phase 1:Active, not recruiting:No publish;;NCT00872014:Phase 2:Completed:No publish;;NCT01214343:Phase 3:Unknown status:No publish;;NCT00712855:Phase 1:Completed:No publish;;NCT03412773:Phase 3:Recruiting:No publish;;NCT01498952:Phase 1:Completed:No publish;;NCT00892424:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT03582618:Phase 2:Not yet recruiting:No publish;;NCT01232296:Phase 2:Completed:No publish;;NCT02988440:Phase 1:Recruiting:No publish;;NCT00956436:Phase 1:Completed:No publish;;NCT00398814:Phase 1:Completed:Preliminary results / Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 16024;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT01988493:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT02560779:Phase 1|Phase 2:Recruiting:No publish;;NCT02400788:Phase 1|Phase 2:Completed:No publish;;NCT02279719:Phase 1|Phase 2:Recruiting:No publish;;NCT01271504:Phase 1|Phase 2:Completed:No publish;;NCT02645981:Phase 2|Phase 3:Recruiting:No publish;;NCT01906216:Phase 2|Phase 3:Recruiting:No publish;;NCT00768937:Phase 1|Phase 2:Completed:No publish;;NCT00882869:Phase 1|Phase 2:Completed:No publish;;NCT02129322:Phase 2:Not yet recruiting:No publish;;NCT02423239:Phase 1:Unknown status:No publish;;NCT02354898:Phase 1:Recruiting:No publish;;NCT03009461:Phase 2:Recruiting:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT03468231:Phase 3:Recruiting:No publish;;NCT01482442:Phase 3:Completed:No publish;;NCT01272557:Phase 2:Unknown status:No publish;;NCT03578874:Phase 2:Recruiting:No publish;;NCT02774187:Phase 3:Active, not recruiting:Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015 Mar 5;10(3):e0119312. doi: 10.1371/journal.pone.0119312. eCollection 2015.;;NCT03518502:Phase 4:Recruiting:Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. doi: 10.1111/j.1365-2036.2011.04697.x. Epub 2011 May 23.;;NCT03434379:Phase 3:Recruiting:No publish;;NCT03298451:Phase 3:Recruiting:No publish;;NCT02867280:Phase 3:Recruiting:No publish;;NCT02562755:Phase 3:Recruiting:No publish;;NCT02733809:Phase 4:Recruiting:No publish;;NCT02716766:Phase 2:Recruiting:No publish;;NCT02672488:Phase 2:Recruiting:No publish;;NCT01761266:Phase 3:Active, not recruiting:No publish;;NCT02576509:Phase 3:Active, not recruiting:No publish;;NCT02504983:Phase 4:Unknown status:Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, Chien RN, Yeh CT. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Pharmacogenomics. 2016 Mar;17(4):353-66. doi: 10.2217/pgs.15.179. Epub 2016 Feb 12.;;NCT02436902:Phase 3:Recruiting:No publish;;NCT02358395:Phase 1:Completed:No publish;;NCT02971696:Phase 3:Completed:No publish;;NCT02961998:Phase 4:Completed:No publish;;NCT02311205:Phase 2:Active, not recruiting:No publish;;NCT01840592:Phase 2:Active, not recruiting:No publish;;NCT00846131:Phase 1:Completed:Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014 Aug;61(2):309-17. doi: 10.1016/j.jhep.2014.03.023. Epub 2014 Mar 27.;;NCT02178358:Phase 2:Active, not recruiting:No publish;;NCT01903694:Phase 3:Completed:No publish;;NCT01897038:Phase 1:Completed:No publish;;NCT01507064:Phase 2:Completed:No publish;;NCT01409499:Phase 4:Unknown status:No publish;;NCT01357486:Phase 2:Completed:No publish;;NCT01308723:Phase 1:Completed:No publish;;NCT01258608:Phase 2:Completed:No publish;;NCT01246986:Phase 2:Active, not recruiting:No publish;;NCT01170104:Phase 2:Unknown status:No publish;;NCT01004003:Phase 2:Completed:No publish;;NCT00987935:Phase 2:Completed:No publish;;NCT00943449:Phase 2:Completed:No publish;;NCT00892658:Phase 1:Active, not recruiting:No publish;;NCT01265576:Phase 2:Unknown status:No publish;;NCT00858871:Phase 3:Completed:No publish;;NCT00844688:Phase 2:Unknown status:No publish;;NCT00478374:Phase 1:Completed:Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15(11):1198-204. doi: 10.1634/theoncologist.2010-0180. Epub 2010 Oct 29.;;NCT00464919:Phase 2:Completed:No publish	No target
trametinib	NCT02292173:Phase 1:Recruiting:No publish;;NCT02042443:Phase 2:Completed:No publish;;NCT02070549:Phase 1:Recruiting:No publish;;NCT02465060:Phase 2:Recruiting:No publish	html not right
pirarubicin,mitomycin and lobaplatin	NCT02301091:Phase 3:Recruiting:No publish	html not right
tas-102	NCT02301104:Phase 1:Completed:No publish	No target
artesunate	NCT02304289:Phase 1:Completed:No publish	No target
tenofovir disoproxil fumarate	NCT02308319:Phase 4:Not yet recruiting:No publish	html not right
pf-04518600	NCT02315066:Phase 1:Recruiting:No publish	html not right
pf-04518600 plus pf-05082566	NCT02315066:Phase 1:Recruiting:No publish	html not right
decitabine	NCT02316028:Phase 1|Phase 2:Completed:No publish	No target
omega-3 fatty acid-based parenteral nutrition	NCT02321202:Phase 4:Completed:No publish	html not right
structolipid	NCT02321202:Phase 4:Completed:No publish	html not right
egm	NCT02338297:Phase 3:Unknown status:No publish	html not right
pva	NCT02338297:Phase 3:Unknown status:No publish	html not right
folfoxiri + bevacizumab	NCT02350530:Phase 2:Recruiting:No publish	html not right
oxaliplatin plus capecitabine	NCT02380131:Phase 4:Unknown status:No publish	html not right
herceptin	NCT02380131:Phase 4:Unknown status:No publish	html not right
rsifn-co	NCT02387307:Phase 1:Unknown status:No publish	html not right
xihuang capsules	NCT02399033:Phase 4:Recruiting:No publish	html not right
resminostat	NCT02400788:Phase 1|Phase 2:Completed:No publish	html not right
tace plus rad-p53 artery injection	NCT02418988:Phase 2:Unknown status:No publish	html not right
jnj-42756493 (erdafitinib)	NCT02421185:Phase 1:Recruiting:No publish	html not right
dexanabinol	NCT02423239:Phase 1:Unknown status:No publish	html not right
galunisertib	NCT02423343:Phase 1|Phase 2:Recruiting:No publish	html not right
5-fluorouracil/leucovorin	NCT02426450:Phase 2:Unknown status:No publish	html not right
ramucirumab	NCT02435433:Phase 3:Recruiting:No publish;;NCT02082210:Phase 1|Phase 2:Completed:No publish;;NCT02572687:Phase 1:Active, not recruiting:No publish;;NCT01246986:Phase 2:Active, not recruiting:No publish	html not right
tace plus sorafenib	NCT02436902:Phase 3:Recruiting:No publish	html not right
thalidomine	NCT02447679:Phase 2:Completed:No publish	html not right
tegafur-uracil	NCT02447679:Phase 2:Completed:No publish	html not right
raltitrexed-based chemotherapy	NCT02453490:Phase 3:Recruiting:No publish	html not right
5-fluorouracil-based chemotherapy	NCT02453490:Phase 3:Recruiting:No publish	html not right
adavosertib	NCT02465060:Phase 2:Recruiting:No publish	html not right
afatinib	NCT02465060:Phase 2:Recruiting:No publish	html not right
binimetinib	NCT02465060:Phase 2:Recruiting:No publish	html not right
capivasertib	NCT02465060:Phase 2:Recruiting:No publish	html not right
crizotinib	NCT02465060:Phase 2:Recruiting:No publish	html not right
dabrafenib	NCT02465060:Phase 2:Recruiting:No publish	html not right
defactinib	NCT02465060:Phase 2:Recruiting:No publish	No target
fgfr inhibitor azd4547	NCT02465060:Phase 2:Recruiting:No publish	html not right
larotrectinib	NCT02465060:Phase 2:Recruiting:No publish	html not right
osimertinib	NCT02465060:Phase 2:Recruiting:No publish	html not right
palbociclib	NCT02465060:Phase 2:Recruiting:No publish	html not right
pi3k-beta inhibitor gsk2636771	NCT02465060:Phase 2:Recruiting:No publish	html not right
sapanisertib	NCT02465060:Phase 2:Recruiting:No publish	html not right
taselisib	NCT02465060:Phase 2:Recruiting:No publish	html not right
vismodegib	NCT02465060:Phase 2:Recruiting:No publish;;NCT01546519:Phase 1:Completed:No publish	html not right
in111-pentetréotide	NCT02465112:Phase 3:Recruiting:No publish	html not right
[18f] fmiso	NCT02471313:Phase 2:Completed:No publish	html not right
oxaliplatin hai	NCT02494973:Phase 2|Phase 3:Recruiting:No publish	html not right
oxaliplatin iv	NCT02494973:Phase 2|Phase 3:Recruiting:No publish	html not right
lv5fu2	NCT02494973:Phase 2|Phase 3:Recruiting:No publish	html not right
blu-554	NCT02508467:Phase 1:Recruiting:No publish	No target
tae plus p53 gene	NCT02509169:Phase 2:Unknown status:No publish	html not right
talimogene laherparepvec	NCT02509507:Phase 1:Recruiting:No publish	html not right
lee011	NCT02524119:Phase 2:Recruiting:No publish	No target
liposomal doxorubicin+gemcitabine	NCT02527772:Phase 2|Phase 3:Active, not recruiting:Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011 Jan 1;117(1):125-33. doi: 10.1002/cncr.25578. Epub 2010 Aug 31.|Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.	html not right
oxy111a	NCT02528526:Phase 1|Phase 2:Unknown status:No publish	html not right
floxuridine (fudr),dexamethasone (dxm), heparin in combination with oxaliplatin and capecitabine (capeox) or in combination with oxaliplatin and leucovorin and 5-fu (mfolfox6)	NCT02529774:Phase 2|Phase 3:Not yet recruiting:No publish	html not right
oxaliplatin and capecitabine (capeox) or oxaliplatin and leucovorin and 5-fu (mfolfox6)	NCT02529774:Phase 2|Phase 3:Not yet recruiting:No publish	html not right
gemox	NCT02534337:Phase 2|Phase 3:Unknown status:No publish	html not right
cefazolin	NCT02534961:Phase 4:Unknown status:No publish	html not right
oxaliplatin and raltitrexed	NCT02557490:Phase 4:Unknown status:No publish	html not right
oxaliplatin and fluorouracil	NCT02557503:Phase 4:Unknown status:No publish	html not right
medi6469	NCT02559024:Phase 1:Active, not recruiting:No publish	html not right
p53 gene therapy	NCT02561546:Phase 2:Unknown status:No publish	html not right
trans-catheter embolization	NCT02561546:Phase 2:Unknown status:No publish	html not right
ro7070179	NCT02564614:Phase 1:Completed:No publish	html not right
mln0128	NCT02575339:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
mln0128 (rp2d)	NCT02575339:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
peginterferon alfa-2a	NCT02576964:Phase 2:Completed:No publish;;NCT03253250:Phase 4:Recruiting:No publish	html not right
individualized chemotherapy	NCT02580253:Phase 2:Not yet recruiting:No publish	html not right
mfolfox6	NCT02580253:Phase 2:Not yet recruiting:No publish;;NCT02494973:Phase 2|Phase 3:Recruiting:No publish;;NCT02102789:Phase 3:Recruiting:No publish	html not right
systemic chemotherapy	NCT02584556:Phase 2|Phase 3:Unknown status:No publish	html not right
transcatheter arterial chemoembolization	NCT02584556:Phase 2|Phase 3:Unknown status:No publish	html not right
s-adenosyl methionine	NCT02586285:Phase 1:Unknown status:No publish	html not right
eadm	NCT02630108:Phase 3:Recruiting:Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.	html not right
ultra-fluid lipiodol	NCT02630108:Phase 3:Recruiting:Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.	html not right
mitomycin (mmc)	NCT02638857:Phase 1|Phase 2:Unknown status:No publish	html not right
epirubicin(eadm)	NCT02638857:Phase 1|Phase 2:Unknown status:No publish	html not right
enzalutamide with sorafenib	NCT02642913:Phase 1|Phase 2:Recruiting:No publish	html not right
enzalutamide	NCT02642913:Phase 1|Phase 2:Recruiting:No publish;;NCT02528643:Phase 2:Active, not recruiting:No publish	html not right
donafenib	NCT02645981:Phase 2|Phase 3:Recruiting:No publish	html not right
transarterial chemoembolization (tace)	NCT02646137:Phase 3:Recruiting:No publish	html not right
smoked plum	NCT02649153:Phase 3:Recruiting:You XM, Mo XS, Ma L, Zhong JH, Qin HG, Lu Z, Xiang BD, Wu FX, Zhao XH, Tang J, Pang YH, Chen J, Li LQ. Randomized Clinical Trial Comparing Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Patients With Hepatocellular Carcinoma After Hepatectomy. Medicine (Baltimore). 2015 Nov;94(45):e1968. doi: 10.1097/MD.0000000000001968.	html not right
gum chewing	NCT02649153:Phase 3:Recruiting:You XM, Mo XS, Ma L, Zhong JH, Qin HG, Lu Z, Xiang BD, Wu FX, Zhao XH, Tang J, Pang YH, Chen J, Li LQ. Randomized Clinical Trial Comparing Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Patients With Hepatocellular Carcinoma After Hepatectomy. Medicine (Baltimore). 2015 Nov;94(45):e1968. doi: 10.1097/MD.0000000000001968.	html not right
entecavir	NCT02650271:Phase 2|Phase 3:Recruiting:Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013 Sep;10(3):158-64. doi: 10.7497/j.issn.2095-3941.2013.03.006.	No target
metatinib tromethamine	NCT02650375:Phase 1:Recruiting:No publish	html not right
sitagliptin	NCT02650427:Phase 1:Recruiting:No publish	No target
recombinant human interleukin-2	NCT02662348:Phase 1:Unknown status:No publish	html not right
her2bi-armed t cells	NCT02662348:Phase 1:Unknown status:No publish	html not right
rose bengal disodium	NCT02693067:Phase 1:Recruiting:No publish	html not right
18f-fluoromisonidazole	NCT02695628:Phase 2:Recruiting:No publish	html not right
tai-gpc3-cart cells	NCT02715362:Phase 1|Phase 2:Recruiting:No publish	html not right
mtl-cebpa	NCT02716012:Phase 1:Recruiting:No publish	html not right
vxm01	NCT02718430:Phase 1:Active, not recruiting:No publish	html not right
adjuvant chemotherapy	NCT02738697:Phase 3:Recruiting:Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G, Rau KM, Yang TS, Jian Z, Liang H, Sun Y. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014 Nov;19(11):1169-78. doi: 10.1634/theoncologist.2014-0190. Epub 2014 Sep 15.	html not right
0.9% normal saline	NCT02744248:Phase 1:Completed:No publish	html not right
iop injection	NCT02744248:Phase 1:Completed:No publish;;NCT03407495:Phase 2:Not yet recruiting:No publish	html not right
whole liver lobe ctace doxorubicin	NCT02753881:Phase 1:Recruiting:No publish	html not right
superselective ctace doxorubicin	NCT02753881:Phase 1:Recruiting:No publish	html not right
medi4736	NCT02754856:Phase 1:Recruiting:No publish;;NCT02572687:Phase 1:Active, not recruiting:No publish	html not right
epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil	NCT02755311:Phase 3:Unknown status:No publish	html not right
tefinostat	NCT02759601:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
oxaliplatin(oxa), 5-fluorouracil (5-fu)	NCT02767375:Phase 2|Phase 3:Recruiting:Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2015 May-Jun;16(3):465-522. doi: 10.3348/kjr.2015.16.3.465. Epub 2015 May 13.	html not right
simeprevir	NCT02771405:Phase 3:Recruiting:No publish	No target
daclatasvir	NCT02771405:Phase 3:Recruiting:No publish	html not right
ledipasvir	NCT02771405:Phase 3:Recruiting:No publish	html not right
sofosbuvir	NCT02771405:Phase 3:Recruiting:No publish;;NCT01559844:Phase 2:Completed:No publish	html not right
ribavirin	NCT02771405:Phase 3:Recruiting:No publish;;NCT01559844:Phase 2:Completed:No publish	html not right
apatinib mesylate tablets	NCT02772029:Phase 1|Phase 2:Unknown status:No publish	html not right
folfox protocol	NCT02774187:Phase 3:Active, not recruiting:Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015 Mar 5;10(3):e0119312. doi: 10.1371/journal.pone.0119312. eCollection 2015.;;NCT03048123:Phase 2:Completed:No publish;;NCT02981498:Phase 2:Recruiting:He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. Cardiovasc Intervent Radiol. 2018 May;41(5):734-743. doi: 10.1007/s00270-017-1874-z. Epub 2018 Jan 11.;;NCT02973685:Phase 3:Recruiting:No publish	html not right
inc280	NCT02795429:Phase 1|Phase 2:Recruiting:No publish;;NCT01737827:Phase 2:Recruiting:No publish	html not right
somatostatin infusion	NCT02799212:Phase 3:Recruiting:No publish	html not right
placebo infusion	NCT02799212:Phase 3:Recruiting:No publish	html not right
anlotinib	NCT02809534:Phase 2:Recruiting:No publish	html not right
entecavir therapy	NCT02829359:Phase 2|Phase 3:Completed:No publish	html not right
h3b-6527	NCT02834780:Phase 1:Recruiting:No publish	No target
ad-p53	NCT02842125:Phase 1|Phase 2:Not yet recruiting:No publish	html not right
xeloda	NCT02842125:Phase 1|Phase 2:Not yet recruiting:No publish	html not right
keytruda	NCT02842125:Phase 1|Phase 2:Not yet recruiting:No publish	html not right
opdivo	NCT02842125:Phase 1|Phase 2:Not yet recruiting:No publish	html not right
tace regimen	NCT02856126:Phase 3:Recruiting:No publish	html not right
haic regimen	NCT02856126:Phase 3:Recruiting:No publish	html not right
oral sorafenib	NCT02856126:Phase 3:Recruiting:No publish	html not right
cc-122	NCT02859324:Phase 1|Phase 2:Recruiting:No publish	No target
cabozantinib s-malate	NCT02867592:Phase 2:Recruiting:No publish	html not right
oxaliplatin intravenous	NCT02885753:Phase 3:Recruiting:No publish	html not right
5 fu	NCT02885753:Phase 3:Recruiting:No publish	html not right
oxaliplatin intra-arteriel	NCT02885753:Phase 3:Recruiting:No publish	html not right
cytoxan	NCT02905188:Phase 1:Not yet recruiting:No publish	html not right
acetaminophen	NCT02911961:Phase 4:Not yet recruiting:No publish	html not right
peri-operative chemotherapy	NCT02912052:Phase 3:Not yet recruiting:No publish	html not right
postoperative chemotherapy	NCT02912052:Phase 3:Not yet recruiting:No publish	html not right
yang yin fu zheng therapy	NCT02927626:Early Phase 1:Recruiting:No publish	html not right
routine medical care	NCT02927626:Early Phase 1:Recruiting:No publish	html not right
abc294640	NCT02939807:Phase 2:Recruiting:No publish	No target
shr-1210	NCT02942329:Phase 1|Phase 2:Recruiting:No publish	html not right
nis793	NCT02947165:Phase 1:Recruiting:No publish	html not right
pdr001	NCT02947165:Phase 1:Recruiting:No publish;;NCT02988440:Phase 1:Recruiting:No publish;;NCT02795429:Phase 1|Phase 2:Recruiting:No publish	html not right
car-t cell	NCT02959151:Phase 1|Phase 2:Recruiting:No publish	html not right
cisplatin and 5-fluorouracil	NCT02967887:Phase 2:Recruiting:No publish	html not right
simvastatin	NCT02968810:Phase 2:Recruiting:No publish	html not right
best supportive care	NCT02971696:Phase 3:Completed:No publish;;NCT00508001:Phase 2:Completed:No publish	html not right
p03277	NCT02973516:Phase 2:Recruiting:No publish	html not right
5-fu, oxaliplatin , leucovorin	NCT02987699:Phase 2:Recruiting:Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.	html not right
normal saline	NCT02987907:Phase 3:Recruiting:No publish	html not right
pembrolizumab (200 mg)	NCT03006926:Phase 1:Recruiting:No publish	html not right
trans-arterial chemoembolization (tace)	NCT03007225:Phase 4:Completed:No publish	html not right
tace with drug eluting beads procedure	NCT03007225:Phase 4:Completed:No publish	html not right
genexol-pm	NCT03008512:Phase 2:Recruiting:No publish	html not right
5fluorouracil	NCT03017326:Phase 3:Recruiting:No publish	html not right
vincristine	NCT03017326:Phase 3:Recruiting:No publish	html not right
atorvastatin	NCT03024684:Phase 4:Recruiting:No publish	html not right
tilmanocept (technetium tc 99m tilmanocept injection)	NCT03029988:Phase 1:Recruiting:No publish	html not right
cetuximab plus folfiri/folfox	NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	html not right
folfiri/folfox/capeox	NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	html not right
lipotecan	NCT03035006:Phase 1|Phase 2:Recruiting:No publish;;NCT02267213:Phase 2:Completed:No publish	html not right
sorafenib (sor)	NCT03037437:Phase 2:Recruiting:No publish	html not right
hydroxychloroquine (hcq)	NCT03037437:Phase 2:Recruiting:No publish	html not right
arm nai-iri + 5-fu + leucovorin (arm a)	NCT03044587:Phase 2:Recruiting:No publish	html not right
arm cisplatin + gemcitabine (arm b)	NCT03044587:Phase 2:Recruiting:No publish	html not right
tace drug protocol	NCT03048123:Phase 2:Completed:No publish;;NCT02973685:Phase 3:Recruiting:No publish	html not right
cbt-501	NCT03053466:Phase 1:Recruiting:No publish	html not right
int230-6	NCT03058289:Phase 1|Phase 2:Recruiting:No publish	html not right
sf1126	NCT03059147:Phase 1:Recruiting:No publish	html not right
celecoxib 200mg oral capsule	NCT03059238:Phase 3:Recruiting:Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016 Oct;26(10):3492-9. doi: 10.1007/s00330-016-4207-8. Epub 2016 Jan 22.	html not right
parecoxib sodium	NCT03059238:Phase 3:Recruiting:Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016 Oct;26(10):3492-9. doi: 10.1007/s00330-016-4207-8. Epub 2016 Jan 22.	html not right
controlled-release oxycodone	NCT03059238:Phase 3:Recruiting:Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016 Oct;26(10):3492-9. doi: 10.1007/s00330-016-4207-8. Epub 2016 Jan 22.	html not right
floxuridine (fudr)	NCT03069950:Phase 2:Recruiting:No publish	html not right
irinotecan (cpt-11)	NCT03069950:Phase 2:Recruiting:No publish	html not right
folfox4	NCT03092895:Phase 2:Recruiting:No publish;;NCT02069041:Phase 1:Completed:No publish;;NCT02534337:Phase 2|Phase 3:Unknown status:No publish;;NCT02527772:Phase 2|Phase 3:Active, not recruiting:Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011 Jan 1;117(1):125-33. doi: 10.1002/cncr.25578. Epub 2010 Aug 31.|Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.;;NCT02452853:Phase 2:Unknown status:No publish;;NCT00874406:Phase 4:Unknown status:No publish	html not right
apatinib	NCT03092895:Phase 2:Recruiting:No publish;;NCT02702323:Phase 2|Phase 3:Not yet recruiting:No publish;;NCT02727309:Phase 1|Phase 2:Recruiting:No publish;;NCT02942329:Phase 1|Phase 2:Recruiting:No publish;;NCT03511703:Phase 2:Not yet recruiting:No publish;;NCT03261791:Phase 2:Recruiting:No publish;;NCT03114085:Phase 2:Not yet recruiting:No publish;;NCT03046979:Phase 2:Recruiting:No publish;;NCT02329860:Phase 3:Active, not recruiting:No publish;;NCT01192971:Phase 2:Completed:No publish	No target
xl888	NCT03095781:Phase 1:Recruiting:No publish	No target
kn035	NCT03101488:Phase 1:Recruiting:No publish	html not right
bumetanide	NCT03107416:Phase 1|Phase 2:Recruiting:No publish	No target
milciclib maleate	NCT03109886:Phase 2:Recruiting:No publish	html not right
68gallium citrate	NCT03116945:Phase 2:Recruiting:Gharib AM, Thomasson D, Li KC. Molecular imaging of hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S153-8.	html not right
gpc3-cart cells	NCT03130712:Phase 1|Phase 2:Recruiting:No publish	html not right
drug eluting bead transarterial chemoembolization	NCT03143270:Early Phase 1:Recruiting:No publish	html not right
nivolumab	NCT03143270:Early Phase 1:Recruiting:No publish;;NCT03572582:Phase 2:Recruiting:No publish;;NCT03203304:Phase 1:Recruiting:No publish;;NCT03299946:Phase 1:Recruiting:No publish;;NCT02423343:Phase 1|Phase 2:Recruiting:No publish;;NCT03071094:Phase 1|Phase 2:Recruiting:No publish;;NCT02859324:Phase 1|Phase 2:Recruiting:No publish;;NCT03511222:Phase 1:Not yet recruiting:No publish;;NCT03222076:Phase 2:Recruiting:No publish;;NCT03418922:Phase 1:Recruiting:No publish;;NCT03382886:Phase 1:Recruiting:No publish;;NCT02576509:Phase 3:Active, not recruiting:No publish	No target
incb062079	NCT03144661:Phase 1:Recruiting:No publish	html not right
pregabalin 150mg	NCT03151213:Phase 4:Recruiting:No publish	html not right
sorafenib 200mg tab	NCT03164382:Phase 3:Recruiting:No publish	html not right
folfox regimen	NCT03164382:Phase 3:Recruiting:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00006479:Phase 3:Unknown status:Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.	html not right
oxaliplatin, cetuximab, bevacizumab, panitumumab, irinotecan, leucovorin, 5fluorouracil	NCT03164655:Phase 2:Not yet recruiting:No publish	html not right
il-2	NCT03175705:Phase 1:Recruiting:No publish;;NCT03175679:Phase 1:Recruiting:No publish	html not right
tegafur	NCT03175705:Phase 1:Recruiting:No publish;;NCT03175679:Phase 1:Recruiting:No publish	html not right
celebrex plus metformin	NCT03184493:Phase 3:Recruiting:No publish	html not right
celebrex	NCT03184493:Phase 3:Recruiting:No publish	html not right
metformin	NCT03184493:Phase 3:Recruiting:No publish;;NCT02431676:Phase 2:Active, not recruiting:No publish;;NCT02672488:Phase 2:Recruiting:No publish	html not right
bushen-jianpi dedoction	NCT03189992:Phase 1:Recruiting:No publish	html not right
cinobufotalin injection	NCT03189992:Phase 1:Recruiting:No publish	html not right
epidoxorubicin and cisplatin and lipiodol	NCT03192644:Phase 3:Recruiting:No publish	html not right
mfolfox6 (oxaliplatin, calcium folinate, and 5-fu)	NCT03192644:Phase 3:Recruiting:No publish;;NCT03192618:Phase 3:Recruiting:No publish	html not right
c188-9	NCT03195699:Phase 1:Recruiting:No publish	No target
perflutren protein-type a microspheres	NCT03199274:Early Phase 1:Recruiting:No publish	html not right
np-g2-044	NCT03199586:Phase 1:Recruiting:No publish	html not right
ima970a plus cv8102 and cyclophosphamide	NCT03203005:Phase 1|Phase 2:Recruiting:No publish	html not right
recombinant human endostatin	NCT03208335:Phase 2:Recruiting:No publish	html not right
urea cream 20%	NCT03212625:Phase 4:Recruiting:No publish	html not right
placebos	NCT03212625:Phase 4:Recruiting:No publish	html not right
primovist	NCT03215355:Phase 4:Not yet recruiting:No publish	html not right
pravastatin pill	NCT03219372:Phase 2:Recruiting:No publish	html not right
arq 087	NCT03230318:Phase 2:Recruiting:No publish;;NCT01752920:Phase 1|Phase 2:Active, not recruiting:No publish	html not right
cpg dna	NCT03235167:Phase 1:Not yet recruiting:No publish	html not right
placebo - concentrate	NCT03235167:Phase 1:Not yet recruiting:No publish	html not right
huachansu pian	NCT03236636:Phase 3:Not yet recruiting:No publish	html not right
sorafenib tosylate tablets	NCT03236649:Phase 3:Not yet recruiting:No publish	html not right
icaritin	NCT03236649:Phase 3:Not yet recruiting:No publish;;NCT03236636:Phase 3:Not yet recruiting:No publish;;NCT01972672:Phase 2:Unknown status:No publish	html not right
chiauranib	NCT03245190:Phase 1:Recruiting:No publish	html not right
etv；tdf；adv	NCT03253250:Phase 4:Recruiting:No publish	html not right
meclizine oral tablet	NCT03253289:Phase 1:Recruiting:No publish	html not right
guadecitabine	NCT03257761:Phase 1:Recruiting:No publish	html not right
opdivo injectable product or keytruda injectable product	NCT03259867:Phase 2:Recruiting:No publish	html not right
atorvastatin 10mg	NCT03275376:Phase 2:Recruiting:No publish	html not right
arginine hydrochloride	NCT03278444:Phase 3:Recruiting:No publish	html not right
trimetazidine hydrochloride	NCT03278444:Phase 3:Recruiting:No publish	html not right
defined green tea catechin extract	NCT03278925:Phase 1:Not yet recruiting:No publish	html not right
avelumab (msb0010718c)	NCT03289533:Phase 1:Recruiting:No publish	html not right
btg-002814 (vandetanib-eluting radiopaque beads)	NCT03291379:Early Phase 1:Recruiting:No publish	html not right
tremelimumab (regimen 1)	NCT03298451:Phase 3:Recruiting:No publish	html not right
tremelimumab (regimen 2)	NCT03298451:Phase 3:Recruiting:No publish	html not right
durvalumab (regimen 1)	NCT03298451:Phase 3:Recruiting:No publish	html not right
durvalumab (regimen 2)	NCT03298451:Phase 3:Recruiting:No publish	html not right
fmiso	NCT03303469:Phase 2:Recruiting:No publish	html not right
gns561	NCT03316222:Phase 1|Phase 2:Recruiting:No publish	html not right
fate-nk100	NCT03319459:Phase 1:Recruiting:No publish	html not right
trastuzumab	NCT03319459:Phase 1:Recruiting:No publish;;NCT01953926:Phase 2:Recruiting:No publish	No target
acetylsalicylic acid	NCT03326791:Phase 2:Recruiting:No publish	html not right
placebo oral tablet	NCT03326791:Phase 2:Recruiting:No publish;;NCT03219372:Phase 2:Recruiting:No publish;;NCT03024684:Phase 4:Recruiting:No publish;;NCT03275376:Phase 2:Recruiting:No publish	html not right
cdx-1140	NCT03329950:Phase 1:Recruiting:No publish	html not right
cobimetinib	NCT03340558:Phase 2:Not yet recruiting:No publish	html not right
regorafenib(stivarga, bay73-4506)	NCT03347292:Phase 1:Recruiting:No publish	html not right
terlipressinum	NCT03352349:Phase 2:Recruiting:No publish	html not right
avelumab	NCT03389126:Phase 2:Recruiting:No publish	html not right
pembrolizumab	NCT03397654:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT02509507:Phase 1:Recruiting:No publish;;NCT02940496:Phase 1|Phase 2:Recruiting:No publish;;NCT03347292:Phase 1:Recruiting:No publish;;NCT03511222:Phase 1:Not yet recruiting:No publish;;NCT01174121:Phase 2:Recruiting:No publish;;NCT03519997:Phase 2:Recruiting:No publish;;NCT03337841:Phase 2:Not yet recruiting:No publish;;NCT03163992:Phase 2:Recruiting:No publish;;NCT03419481:Phase 2:Recruiting:No publish;;NCT02658019:Phase 2:Active, not recruiting:No publish	No target
standard chemotherapy	NCT03398291:Phase 3:Not yet recruiting:No publish	html not right
folfoxiri and bevacizumab	NCT03401294:Phase 2:Not yet recruiting:No publish	html not right
rintatolimod	NCT03403634:Early Phase 1:Recruiting:No publish	html not right
lumason	NCT03407001:Early Phase 1:Recruiting:No publish	html not right
bgb-a317	NCT03419897:Phase 2:Recruiting:No publish;;NCT03412773:Phase 3:Recruiting:No publish	html not right
icosapent ethyl	NCT03428477:Phase 3:Recruiting:No publish	html not right
lenvatinib	NCT03433703:Phase 2:Recruiting:No publish;;NCT03418922:Phase 1:Recruiting:No publish;;NCT03006926:Phase 1:Recruiting:No publish;;NCT02953743:Phase 1:Active, not recruiting:No publish;;NCT01761266:Phase 3:Active, not recruiting:No publish	html not right
atezolizumab	NCT03434379:Phase 3:Recruiting:No publish	No target
pt-112 injection	NCT03439761:Phase 1|Phase 2:Recruiting:No publish	html not right
para-toluenesulfonamide	NCT03447951:Phase 2:Not yet recruiting:No publish	html not right
shr 1210+apatinib	NCT03463876:Phase 2:Recruiting:No publish	html not right
haic of folfox	NCT03468231:Phase 3:Recruiting:No publish	html not right
haic of oxa	NCT03468231:Phase 3:Recruiting:No publish	html not right
folfox	NCT03469479:Phase 3:Recruiting:No publish	html not right
phase 1 : regorafenib	NCT03475953:Phase 1|Phase 2:Recruiting:No publish	html not right
phase 1 : avelumab	NCT03475953:Phase 1|Phase 2:Recruiting:No publish	html not right
phase 2 : regorafenib	NCT03475953:Phase 1|Phase 2:Recruiting:No publish	html not right
phase 2 : avelumab	NCT03475953:Phase 1|Phase 2:Recruiting:No publish	html not right
5-fluorouracil	NCT03493048:Phase 2:Recruiting:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.;;NCT01226719:Phase 2:Completed:No publish	html not right
aslan001	NCT03499626:Phase 1|Phase 2:Recruiting:No publish	html not right
fudr	NCT03500874:Phase 3:Recruiting:No publish	html not right
5fu	NCT03500874:Phase 3:Recruiting:No publish	html not right
cgx1321	NCT03507998:Phase 1:Recruiting:No publish	html not right
nivolumab, ipilimumab	NCT03510871:Phase 2:Not yet recruiting:No publish	html not right
vorolanib	NCT03511222:Phase 1:Not yet recruiting:No publish	html not right
chemotherapy drugs+iodized oil	NCT03511703:Phase 2:Not yet recruiting:No publish	html not right
babaodan oral capsule	NCT03515369:Phase 4:Not yet recruiting:No publish	html not right
placebo oral capsule	NCT03515369:Phase 4:Not yet recruiting:No publish	html not right
brivanib 800 mg, qd	NCT03516071:Phase 2:Recruiting:No publish	html not right
brivanib 400 mg, bid	NCT03516071:Phase 2:Recruiting:No publish	html not right
ts-1 combined with cisplatin	NCT03519074:Phase 2:Recruiting:No publish	html not right
bavituximab	NCT03519997:Phase 2:Recruiting:No publish	html not right
etoposide	NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00007813:Phase 1:Unknown status:Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.;;NCT00002854:Phase 1:Completed:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT00003597:Phase 1:Completed:Angiolillo AL, Davenport V, Bonilla MA, van de Ven C, Ayello J, Militano O, Miller LL, Krailo M, Reaman G, Cairo MS; Children's Oncology Group. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005 Apr 1;11(7):2644-50.	html not right
gemcitabine	NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT01525069:Phase 1:Recruiting:No publish;;NCT02423239:Phase 1:Unknown status:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT00844688:Phase 2:Unknown status:No publish;;NCT00142467:Phase 2:Completed:No publish	html not right
durvalumab	NCT03539822:Phase 1:Not yet recruiting:No publish;;NCT03298451:Phase 3:Recruiting:No publish	No target
administration of daa-based treatment	NCT03551444:Phase 3:Recruiting:No publish	html not right
nab-paclitaxel	NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT02423239:Phase 1:Unknown status:No publish	html not right
tace	NCT03572582:Phase 2:Recruiting:No publish;;NCT02956772:Phase 2:Not yet recruiting:No publish;;NCT02418988:Phase 2:Unknown status:No publish;;NCT00921531:Phase 3:Unknown status:No publish	html not right
cvm-1118	NCT03582618:Phase 2:Not yet recruiting:No publish	html not right
lutetium lu 177-dotatate	NCT03590119:Phase 2|Phase 3:Not yet recruiting:No publish	html not right
atg-008	NCT03591965:Phase 2:Not yet recruiting:No publish	html not right
obi-3424	NCT03592264:Phase 1|Phase 2:Recruiting:No publish	html not right
